<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pharmacokinet Pharmacodyn</journal-id><journal-id journal-id-type="iso-abbrev">J Pharmacokinet Pharmacodyn</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Journal of Pharmacokinetics and Pharmacodynamics</journal-title></journal-title-group><issn pub-type="ppub">1567-567X</issn><issn pub-type="epub">1573-8744</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12095442</article-id><article-id pub-id-type="pmcid-ver">PMC12095442.1</article-id><article-id pub-id-type="pmcaid">12095442</article-id><article-id pub-id-type="pmcaiid">12095442</article-id><article-id pub-id-type="pmid">40399699</article-id><article-id pub-id-type="doi">10.1007/s10928-025-09971-w</article-id><article-id pub-id-type="publisher-id">9971</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>van der Walt</surname><given-names initials="JS">Jan-Stefan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilkins</surname><given-names initials="J">Justin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khandelwal</surname><given-names initials="A">Akash</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Venkatakrishnan</surname><given-names initials="K">Karthik</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Milenkovi&#263;-Gri&#353;i&#263;</surname><given-names initials="AM">Ana-Marija</given-names></name><address><email>ana-marija.milenkovic@emdgroup.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Occams, Amstelveen, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04b2dty93</institution-id><institution-id institution-id-type="GRID">grid.39009.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 0672 7022</institution-id><institution>The Healthcare Business of Merck KGaA, </institution></institution-wrap>Darmstadt, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/027zrs220</institution-id><institution-id institution-id-type="GRID">grid.481568.6</institution-id><institution>EMD Serono, </institution></institution-wrap>Billerica, MA USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>52</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">489031</issue-id><elocation-id>33</elocation-id><history><date date-type="received"><day>6</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>23</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-23 00:25:25.033"><day>23</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10928_2025_Article_9971.pdf"/><abstract id="Abs1"><p id="Par1">The aim of the analysis was to develop a phenomenological longitudinal population pharmacokinetics (PK)-anti-drug antibodies (ADA) model to enable an informed and quantitative framework for assessment of ADA influence. Data used were from seven clinical studies of avelumab across drug development phases in patients with several tumor types. ADA as covariate in a population PK model, and Markov models of ADA status (ADA+&#8201;or ADA&#8722;) were investigated. Finally, a joint PK-ADA model was developed. In the population PK models that evaluated ADA as a covariate, the clearance increase attributable to ADA+&#8201;status was 8.5% (time-varying ADA) to 19.9% (time-invariant ADA with inter-occasion variability in clearance). With a discrete-time Markov model (DTMM), tumor type was identified as a significant covariate on the probability of ADA&#8722; to ADA+&#8201;transition. When ADA time course predicted by the DTMM model was implemented as a covariate in the population PK model, an increase in avelumab clearance of 11&#8211;41% was estimated depending on tumor type. With a continuous-time Markov model (CTMM), in addition to tumor type, baseline ADA status was identified to significantly influence the ADA&#8722; to ADA+&#8201;transition rate constant. The joint PK-CTMM model estimated the maximal increase in CL due to ADA as 15% and a&#160;decrease in ADA&#8722; to ADA+&#8201;transition rate of up to 37% with increasing avelumab concentration, with 50% of the maximum decrease occurring at 349 &#181;g/mL. The present work established a framework for the assessment of interactions between PK and immunogenicity for therapeutic proteins.</p><sec><title>Graphical Abstract</title><p id="Par2">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO1" orientation="portrait" xlink:href="10928_2025_9971_Figa_HTML.jpg"/></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10928-025-09971-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Therapeutic proteins</kwd><kwd>Immunogenicity/anti-drug antibodies</kwd><kwd>Bidirectional model</kwd><kwd>Avelumab</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Immunogenicity, the development of anti-drug antibodies (ADA), is an important characteristic of therapeutic proteins, affecting pharmacokinetics (PK) and pharmacodynamics (PD), including drug efficacy and safety [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Immunogenicity is an inherent characteristic of therapeutic proteins, resulting from natural immune processes, but ADA development can also be influenced by intrinsic and extrinsic factors such as the underlying disease and its status, or comedication with immune system-altering drugs, such as corticosteroids, immunomodulators, or chemotherapy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par4">Mechanistically, all ADA form immune complexes with drug molecules which are subsequently eliminated, thereby increasing the clearance of the drug to varying extents. At the same time, ADA (especially neutralizing ADA, which bind to target-binding sites on the drug molecule) can inhibit drug molecules binding to their targets, thus potentially negating the pharmacological activity of the drug, in addition to lowering its exposure owing to increased clearance (CL). ADA-drug immune complexes can also cause anaphylactic/hypersensitivity reactions. For cancer immunotherapies, it has been proposed that development of ADA might be a surrogate marker of immune system activation and therefore drug efficacy [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par5">Due to the complexity inherent in ADA (different IgG classes, only semi-quantitative analytical methods, and an array of other complications), the kinetics of ADA development are difficult to characterize [<xref ref-type="bibr" rid="CR5">5</xref>]. The effects of ADA on PK, efficacy, and safety of drugs are often investigated by classifying patients as ADA+&#8201;(developed ADA at any point during the trial) or ADA&#8722; (never developed ADA during the trial) in a time-constant manner. This way, valuable information is lost, whereas modeling ADA structurally and in a time-varying manner would reduce this information loss by enabling the use of ADA information over time. Furthermore, assigning ADA status on patient level (ADA ever/never) is pharmacologically not appropriate for describing causal relationships and additionally introduces immortal-time bias [<xref ref-type="bibr" rid="CR6">6</xref>], as this non-baseline variable is treated as known at baseline, thereby confounding the results of such analyses. The fact that ADA are commonly reported as titers, not absolute concentrations, further complicates analysis in a quantitative mechanistic manner. Finally, simulations with ADA are typically not feasible in the absence of a model describing their development.</p><p id="Par6">Published population models that account for ADA usually include overall ADA status (ever/never or, less frequently, ADA as a time-varying covariate) as a covariate on CL or volume of distribution (V), not as a part of a structural model [<xref ref-type="bibr" rid="CR7">7</xref>]. Further, many approaches are limited to accounting only for patients who develop ADA and are not suitable for describing ADA&#8722; patients. While limitations inherent to the observed ADA data (such as having only titers available) cannot be fully circumvented, a longitudinal PK-ADA model would theoretically enable an informed and less biased framework for assessment of ADA influence.</p><p id="Par7">Avelumab is a human immunoglobulin G1 (IgG1) anti-programmed death ligand 1 (PD-L1) monoclonal antibody [<xref ref-type="bibr" rid="CR8">8</xref>] with a wild-type fragment crystallizable (Fc) region, indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC), first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy, and in combination with axitinib for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par8">The overall aim of this investigation was to develop a bidirectional joint PK-ADA model on an&#160;immuno-oncology data set to establish a framework for assessing the impact&#160;of immunogenicity on drug PK. As the first step, within this project, two alternative approaches to account for ADA were investigated: (1) ADA as a time-varying covariate in a population PK model, and (2) a Markov model of ADA status linked to a population PK model. Markov models are mathematical models that describe systems which transition from one state to another, with the probability of each transition depending only on the current state and not on the previous states [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par9">Apart from the interaction between systemic drug concentrations and ADA status, the ADA status analysis included investigating covariate effects on ADA status transitions. Potential effects of tumor type were also investigated within the covariate analysis.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data</title><p id="Par10">The analysis was performed using pooled data of patients treated with avelumab across drug development phases with different oncology indications from multiple clinical trials. An overview of the analyzed patient population is given in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Data from 1892 patients with evaluable PK data were used in the analysis and were split into two subsets stratified by ADA incidence (ever vs never ADA+): a subset for model development (1513 patients,&#8201;~&#8201;80% of data) and a validation subset (379 patients,&#8201;~&#8201;20% of data). Previously, a population PK model developed on data from 3 of the 7 clinical trials was published [<xref ref-type="bibr" rid="CR11">11</xref>].<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Summary of clinical data included in the analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">JAVELIN Solid Tumor</th><th align="left" colspan="1" rowspan="1">JAVELIN Solid Tumor JPN</th><th align="left" colspan="1" rowspan="1">JAVELIN Merkel 200</th><th align="left" colspan="1" rowspan="1">JAVELIN Lung 200</th><th align="left" colspan="1" rowspan="1">JAVELIN Lung 100</th><th align="left" colspan="1" rowspan="1">JAVELIN Gastric 100</th><th align="left" colspan="1" rowspan="1">JAVELIN Gastric 300</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Description</td><td align="left" colspan="1" rowspan="1">Avelumab in metastatic or locally advanced solid tumors&#160;(UC cohorts)</td><td align="left" colspan="1" rowspan="1">Avelumab in metastatic or locally advanced solid tumors</td><td align="left" colspan="1" rowspan="1">Avelumab in 2L Merkel cell carcinoma</td><td align="left" colspan="1" rowspan="1">Avelumab in 2L&#160;NSCLC</td><td align="left" colspan="1" rowspan="1">Avelumab in 1L NSCLC</td><td align="left" colspan="1" rowspan="1">Avelumab in 1L maintenance gastric cancer</td><td align="left" colspan="1" rowspan="1">Avelumab in 3L gastric cancer</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase</td><td align="left" colspan="1" rowspan="1">I/Ib</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">III</td></tr><tr><td align="left" colspan="1" rowspan="1">ClinicalTrials.gov ID</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01772004">NCT01772004</ext-link></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01943461">NCT01943461</ext-link></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02155647">NCT02155647</ext-link></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02395172">NCT02395172</ext-link></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02576574">NCT02576574</ext-link></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02625610">NCT02625610</ext-link></td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02625623">NCT02625623</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Indication</td><td align="left" colspan="1" rowspan="1">2L&#160;UC</td><td align="left" colspan="1" rowspan="1">Solid tumors in Japanese patients; expansion in GC</td><td align="left" colspan="1" rowspan="1">2L MCC</td><td align="left" colspan="1" rowspan="1">2L NSCLC</td><td align="left" colspan="1" rowspan="1">1L NSCLC</td><td align="left" colspan="1" rowspan="1">1L GC/GEJC</td><td align="left" colspan="1" rowspan="1">3L GC/GEJC</td></tr><tr><td align="left" colspan="1" rowspan="1">Dosing regimen(s)</td><td align="left" colspan="1" rowspan="1">10&#160;mg/kg Q2W</td><td align="left" colspan="1" rowspan="1">3&#160;mg/kg Q2W, 10&#160;mg/kg Q2W, 20&#160;mg/kg Q2W</td><td align="left" colspan="1" rowspan="1">10&#160;mg/kg Q2W</td><td align="left" colspan="1" rowspan="1">10&#160;mg/kg Q2W</td><td align="left" colspan="1" rowspan="1">10&#160;mg/kg Q2W or&#160;10&#160;mg/kg Q1W for 12&#160;weeks then 10&#160;mg/kg Q2W</td><td align="left" colspan="1" rowspan="1">10&#160;mg/kg Q2W</td><td align="left" colspan="1" rowspan="1">10&#160;mg/kg Q2W</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of patients included in the analysis</td><td align="left" colspan="1" rowspan="1">249</td><td align="left" colspan="1" rowspan="1">57</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">393</td><td align="left" colspan="1" rowspan="1">688</td><td align="left" colspan="1" rowspan="1">233</td><td align="left" colspan="1" rowspan="1">184</td></tr><tr><td align="left" colspan="1" rowspan="1">Patients ever ADA+&#8201;in the analyzed data&#160;set (%)</td><td align="left" colspan="1" rowspan="1">7.6</td><td align="left" colspan="1" rowspan="1">8.8</td><td align="left" colspan="1" rowspan="1">5.7</td><td align="left" colspan="1" rowspan="1">13.0</td><td align="left" colspan="1" rowspan="1">15.3</td><td align="left" colspan="1" rowspan="1">9.0</td><td align="left" colspan="1" rowspan="1">9.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of ADA samples (sampling days)</td><td align="left" colspan="1" rowspan="1">8 (0, 14, 28, 42, 56, 60, 84, 168)</td><td align="left" colspan="1" rowspan="1">3 (14, 28, 42)</td><td align="left" colspan="1" rowspan="1">5 (0, 14, 28, 42, 84)</td><td align="left" colspan="1" rowspan="1">8 (0, 14, 28, 42, 84, 124, 168, 252)</td><td align="left" colspan="1" rowspan="1">17 (0, 28, 42, 56, 84, 140, 168, 252, 336, 420, 504, 558, 672, 756, 850, 924, 1008)</td><td align="left" colspan="1" rowspan="1">7 (0, 14, 28, 42, 84, 124, 168)</td><td align="left" colspan="1" rowspan="1">5 (0, 14, 28, 42, 84)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">1L</italic> first line, <italic toggle="yes">2L</italic> second line, <italic toggle="yes">3L</italic> third line, <italic toggle="yes">GC</italic> gastric cancer, <italic toggle="yes">GEJC</italic> gastroesophageal junction cancer, <italic toggle="yes">MCC</italic> Merkel cell carcinoma, <italic toggle="yes">NSCLC</italic> non-small cell lung cancer, <italic toggle="yes">Q2W</italic>&#160;every two weeks, <italic toggle="yes">Q1W</italic> every week, <italic toggle="yes">UC</italic> urothelial carcinoma</p></table-wrap-foot></table-wrap></p><p id="Par11">Avelumab concentrations were quantified using an immunoassay sandwich method (interrun coefficient of variation [CV]&#8201;&#8804;&#8201;16.1%, bias [absolute value]&#8201;&#8804;&#8201;15.5%, total interrun error&#8201;&#8804;&#8201;19.1%). The lower limit of quantification was 0.2&#160;&#956;g/mL [<xref ref-type="bibr" rid="CR11">11</xref>]. ADA testing was conducted using a tiered assay approach, whereby samples that were screened and confirmed positive for ADA were subsequently analyzed to determine the titer using the homogeneous bridging electro chemiluminescent immuno-assay [<xref ref-type="bibr" rid="CR12">12</xref>]. The following numbers of data points/participants were used for the model development and evaluation: PK development, 12,707/1513; PK evaluation, 3362/377; CTMM development, 14,874 /1495; CTMM evaluation, 3925/375; DTMM development, 14,247/1513; and DTMM evaluation, 3766/378. The average number of ADA samples and collection times are provided in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Missing ADA data were ignored in the analyses. There was no minimum ADA data requirement for a patient to be considered evaluable. Only 7 patients with neutralizing antibody were reported, and for 76 data points, the neutralizing antibody information was missing.</p></sec><sec id="Sec4"><title>Avelumab population PK model</title><p id="Par12">A previously-developed population PK model for avelumab formed the basis for PK-ADA model development [<xref ref-type="bibr" rid="CR11">11</xref>]. This model was 2-compartmental, with time-dependent clearance (CL; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Decrease in CL was modeled as a sigmoid maximal inhibitory response process [<xref ref-type="bibr" rid="CR13">13</xref>]:<disp-formula id="Equa"><alternatives><tex-math id="d33e473">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$C{L}_{i,t}=TVCL\cdot {\text{exp}}\left(\frac{{I}_{max,i}\cdot {t}_{i}^{\gamma }}{{T}_{50}^{\gamma }+{t}_{i}^{\gamma }}\right)\cdot {\text{exp}}({\eta }_{CL,i})$$\end{document}</tex-math><mml:math id="d33e478" display="block"><mml:mrow><mml:mi>C</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:mi>V</mml:mi><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>&#183;</mml:mo><mml:mtext>exp</mml:mtext><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>&#947;</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>T</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mi>&#947;</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mi>&#947;</mml:mi></mml:msubsup></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>&#183;</mml:mo><mml:mtext>exp</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equa.gif"/></alternatives></disp-formula></p><p id="Par13">Here, <inline-formula id="IEq1"><alternatives><tex-math id="d33e541">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${CL}_{i,t}$$\end{document}</tex-math><mml:math id="d33e546"><mml:msub><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq1.gif"/></alternatives></inline-formula> is CL in individual <inline-formula id="IEq2"><alternatives><tex-math id="d33e557">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e562"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at time <inline-formula id="IEq3"><alternatives><tex-math id="d33e566">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="d33e571"><mml:mi>t</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq3.gif"/></alternatives></inline-formula>, <inline-formula id="IEq4"><alternatives><tex-math id="d33e575">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$TVCL$$\end{document}</tex-math><mml:math id="d33e580"><mml:mrow><mml:mi mathvariant="italic">TVCL</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq4.gif"/></alternatives></inline-formula> is the typical value of CL in the population, <inline-formula id="IEq5"><alternatives><tex-math id="d33e586">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}_{max,i}$$\end{document}</tex-math><mml:math id="d33e591"><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq5.gif"/></alternatives></inline-formula> is the maximal possible change in CL relative to baseline for individual <inline-formula id="IEq6"><alternatives><tex-math id="d33e603">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e608"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, <inline-formula id="IEq7"><alternatives><tex-math id="d33e612">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${t}_{i}$$\end{document}</tex-math><mml:math id="d33e617"><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq7.gif"/></alternatives></inline-formula> is the time after first dose in individual <inline-formula id="IEq8"><alternatives><tex-math id="d33e623">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e628"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, <inline-formula id="IEq9"><alternatives><tex-math id="d33e632">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${T}_{50}$$\end{document}</tex-math><mml:math id="d33e637"><mml:msub><mml:mi>T</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq9.gif"/></alternatives></inline-formula> is the time at which 50% of <inline-formula id="IEq10"><alternatives><tex-math id="d33e643">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}_{max}$$\end{document}</tex-math><mml:math id="d33e648"><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq10.gif"/></alternatives></inline-formula> is reached, <inline-formula id="IEq11"><alternatives><tex-math id="d33e656">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma$$\end{document}</tex-math><mml:math id="d33e661"><mml:mi>&#947;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq11.gif"/></alternatives></inline-formula> describes the shape of the relationship, and <inline-formula id="IEq12"><alternatives><tex-math id="d33e666">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\eta }_{CL,i}$$\end{document}</tex-math><mml:math id="d33e671"><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq12.gif"/></alternatives></inline-formula> is interindividual variability (IIV) in CL for individual <inline-formula id="IEq13"><alternatives><tex-math id="d33e681">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e686"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, defined as being normally distributed with a mean of 0 and variance of <inline-formula id="IEq14"><alternatives><tex-math id="d33e690">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\omega }_{CL}^{2}$$\end{document}</tex-math><mml:math id="d33e695"><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq14.gif"/></alternatives></inline-formula>. In addition to CL, IIV was included on central volume of distribution (V1) and <inline-formula id="IEq15"><alternatives><tex-math id="d33e704">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}_{max}$$\end{document}</tex-math><mml:math id="d33e709"><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq10.gif"/></alternatives></inline-formula> (additively for the latter). The residual error was described by a combined additive and proportional error model. For the current analysis all covariate effects were removed except body weight as a covariate on CL and V1 using standard allometry coefficients [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec5"><title>Joint PK-ADA model</title><p id="Par14">Two approaches to model ADA data were investigated: (1) ADA as a covariate in the population PK model, and (2) Markov models of ADA status. Finally, a PK-ADA model linked the Markov model for ADA status to the population PK model to assess the bidirectional effect of ADA status on PK and drug exposure on ADA status simultaneously. The modeling strategy started with model development for models with lower complexity/computational burden and progressed to models with higher complexity/computational burden. ADA status was evaluated for effect on avelumab PK as a categorical covariate on avelumab clearance using different categorizations of ADA status: ADAEVER (time-invariant, ever vs never ADA+), ADAONCE (time-varying, ADA+&#8201;at first appearance of ADA and thereafter), and&#160;ADALOCF (time-varying, ADA+&#8201;vs ADA&#8722;) as graphically demonstrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Categories of time-variant ADA, using a representative patient</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig1_HTML.jpg"/></fig></p><p id="Par15">The ADA part of the joint model was considered be Markovian in nature, since it is likely to depend on state transitions over time: ADA&#8722; to ADA+&#8201;, and back again, based on the previous state, and on time. ADA status was modeled using two-state discrete-time (DTMM) and two-state continuous-time (CTMM) Markov models. The Markov ADA-models were evaluated using VPCs for both the probability of ADA status as well as the probability to change ADA state or to remain in the same ADA state. Covariate relationships identified for the DTMM were included in the CTMM. The joint PK-ADA model was constructed by linking the population PK model to the CTMM to assess the effects of ADA on avelumab clearance and the effect of avelumab exposure on ADA status.</p></sec><sec id="Sec6"><title>Discrete-time Markov models</title><p id="Par16">Discrete-time Markov models (DTMMs) assume time to be a discrete variable, the recorded observation times in a clinical study. DTMM equations describe the transition probability from state <inline-formula id="IEq16"><alternatives><tex-math id="d33e740">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${k}_{j-1}$$\end{document}</tex-math><mml:math id="d33e745"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq16.gif"/></alternatives></inline-formula> to state <inline-formula id="IEq17"><alternatives><tex-math id="d33e754">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${k}_{j}$$\end{document}</tex-math><mml:math id="d33e759"><mml:msub><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq17.gif"/></alternatives></inline-formula>, or more simply, the probability of each state <inline-formula id="IEq18"><alternatives><tex-math id="d33e765">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${k}_{j}$$\end{document}</tex-math><mml:math id="d33e770"><mml:msub><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq17.gif"/></alternatives></inline-formula> at the current occasion <inline-formula id="IEq19"><alternatives><tex-math id="d33e776">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e781"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula> given that state <inline-formula id="IEq20"><alternatives><tex-math id="d33e785">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${k}_{j-1}$$\end{document}</tex-math><mml:math id="d33e790"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq16.gif"/></alternatives></inline-formula> was observed at the previous occasion <inline-formula id="IEq21"><alternatives><tex-math id="d33e800">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e805"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>&#8722;1 [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par17">The DTMM (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) may be summarized as follows:<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Structure of the discrete-time Markov model. <inline-formula id="IEq144"><alternatives><tex-math id="d33e823">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${p}_{10}:$$\end{document}</tex-math><mml:math id="d33e828"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mo>:</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq144.gif"/></alternatives></inline-formula> probability to transition from ADA+&#8201;to ADA&#8722;; <inline-formula id="IEq145"><alternatives><tex-math id="d33e836">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\varvec{p}}}_{01}$$\end{document}</tex-math><mml:math id="d33e841"><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">p</mml:mi></mml:mrow><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq145.gif"/></alternatives></inline-formula>: probability to transition from ADA&#8722; to ADA+</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig2_HTML.jpg"/></fig><disp-formula id="Equb"><alternatives><tex-math id="d33e851">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{01,i,j}=P({Y}_{i,j}=\left.1\right|{Y}_{i,j-1}=0)$$\end{document}</tex-math><mml:math id="d33e856" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="|"><mml:mn>1</mml:mn></mml:mfenced><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equb.gif"/></alternatives></disp-formula><disp-formula id="Equc"><alternatives><tex-math id="d33e893">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{00,i,j}=P\left({Y}_{i,j}=\left.0\right|{Y}_{i,j-1}=0\right)=1-{P}_{01,i,j}$$\end{document}</tex-math><mml:math id="d33e898" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>00</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="|"><mml:mn>0</mml:mn></mml:mfenced><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equc.gif"/></alternatives></disp-formula><disp-formula id="Equd"><alternatives><tex-math id="d33e942">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{10,i,j}=P({Y}_{i,j}=\left.0\right|{Y}_{i,j-1}=1)$$\end{document}</tex-math><mml:math id="d33e947" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="|"><mml:mn>0</mml:mn></mml:mfenced><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equd.gif"/></alternatives></disp-formula><disp-formula id="Eque"><alternatives><tex-math id="d33e984">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{11,i,j}=P({Y}_{i,j}=\left.1\right|{Y}_{i,j-1}=1)=1-{P}_{10,i,j}$$\end{document}</tex-math><mml:math id="d33e989" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="|"><mml:mn>1</mml:mn></mml:mfenced><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Eque.gif"/></alternatives></disp-formula></p><p id="Par18">Here, <inline-formula id="IEq22"><alternatives><tex-math id="d33e1039">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{01}$$\end{document}</tex-math><mml:math id="d33e1044"><mml:msub><mml:mi>P</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq22.gif"/></alternatives></inline-formula> is the probability of a transition from ADA&#8722; (state 0) to ADA+&#8201;(state 1) in individual <inline-formula id="IEq23"><alternatives><tex-math id="d33e1050">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1055"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at observation occasion <inline-formula id="IEq24"><alternatives><tex-math id="d33e1059">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1064"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>, <inline-formula id="IEq25"><alternatives><tex-math id="d33e1068">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{10}$$\end{document}</tex-math><mml:math id="d33e1073"><mml:msub><mml:mi>P</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq25.gif"/></alternatives></inline-formula> is the probability of a transition from ADA+&#8201;to ADA&#8722; in individual <inline-formula id="IEq26"><alternatives><tex-math id="d33e1079">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1084"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at observation occasion <inline-formula id="IEq27"><alternatives><tex-math id="d33e1089">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1094"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>, <inline-formula id="IEq28"><alternatives><tex-math id="d33e1098">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{00,i,j}$$\end{document}</tex-math><mml:math id="d33e1103"><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>00</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq28.gif"/></alternatives></inline-formula> is the probability that ADA remains negative in individual <inline-formula id="IEq29"><alternatives><tex-math id="d33e1114">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1119"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at observation occasion <inline-formula id="IEq30"><alternatives><tex-math id="d33e1123">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1128"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq31"><alternatives><tex-math id="d33e1132">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{11,i,j}$$\end{document}</tex-math><mml:math id="d33e1137"><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq31.gif"/></alternatives></inline-formula> is the probability that ADA remains positive in individual <inline-formula id="IEq32"><alternatives><tex-math id="d33e1148">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1153"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at observation occasion <inline-formula id="IEq33"><alternatives><tex-math id="d33e1158">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1163"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>. <inline-formula id="IEq34"><alternatives><tex-math id="d33e1167">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${Y}_{i,j}$$\end{document}</tex-math><mml:math id="d33e1172"><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq34.gif"/></alternatives></inline-formula> is the observed value of ADA (+&#8201;or &#8722;) in individual <inline-formula id="IEq35"><alternatives><tex-math id="d33e1181">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1186"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at observation occasion <inline-formula id="IEq36"><alternatives><tex-math id="d33e1190">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1195"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>, while <inline-formula id="IEq37"><alternatives><tex-math id="d33e1199">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${Y}_{i,j-1}$$\end{document}</tex-math><mml:math id="d33e1204"><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq37.gif"/></alternatives></inline-formula> is the observed value of ADA (+&#8201;or &#8722;) in individual <inline-formula id="IEq38"><alternatives><tex-math id="d33e1215">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1220"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at preceding observation occasion <inline-formula id="IEq39"><alternatives><tex-math id="d33e1225">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1230"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>&#8722;1.</p><p id="Par19">The probabilities were estimated using a logit transformation:<disp-formula id="Equf"><alternatives><tex-math id="d33e1236">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_{{01,i}} = \frac{1}{{\left( {1 + \exp ^{{\left( { - \left( {TVP_{{01}} + \eta_{P{_{01}}} } \right)} \right)}} } \right)}}$$\end{document}</tex-math><mml:math id="d33e1241" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mmultiscripts><mml:mo>exp</mml:mo><mml:mrow/><mml:mfenced close=")" open="("><mml:mrow><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>T</mml:mi><mml:mi>V</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>01</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mmultiscripts><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mmultiscripts><mml:mrow/><mml:mn>01</mml:mn><mml:mrow/></mml:mmultiscripts></mml:mrow><mml:mrow/></mml:mmultiscripts></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mmultiscripts></mml:mrow></mml:mfenced></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equf.gif"/></alternatives></disp-formula></p><p id="Par20">Here, <inline-formula id="IEq40"><alternatives><tex-math id="d33e1282">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{01,i}$$\end{document}</tex-math><mml:math id="d33e1287"><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq40.gif"/></alternatives></inline-formula> is the individual realization of patient <inline-formula id="IEq41"><alternatives><tex-math id="d33e1296">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1301"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>&#8217;s probability to transition from ADA&#8722; to ADA+&#8201;where <inline-formula id="IEq42"><alternatives><tex-math id="d33e1305">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${TVP}_{01}$$\end{document}</tex-math><mml:math id="d33e1310"><mml:msub><mml:mrow><mml:mi mathvariant="italic">TVP</mml:mi></mml:mrow><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq42.gif"/></alternatives></inline-formula> is the typical value of the probability in the population, and <inline-formula id="IEq43"><alternatives><tex-math id="d33e1318">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\eta }_{{P}_{01}}$$\end{document}</tex-math><mml:math id="d33e1323"><mml:msub><mml:mi>&#951;</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq43.gif"/></alternatives></inline-formula> is the IIV defined as being normally distributed with a mean of 0 and variance of <inline-formula id="IEq44"><alternatives><tex-math id="d33e1331">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\omega }_{{P}_{01}}^{2}$$\end{document}</tex-math><mml:math id="d33e1336"><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq44.gif"/></alternatives></inline-formula>.</p></sec><sec id="Sec7"><title>Continuous-time Markov models</title><p id="Par21">The continuous-time Markov model (CTMM) is more appropriate for non-uniform observation times, although for two-state data, the DTMM and CTMM methods may produce similar results for naturally discretized data (e.g. prespecified time points based on clinical trial designs) [<xref ref-type="bibr" rid="CR10">10</xref>]. In this method, the influence of the previous state on the probability of the current state typically decreases with increasing time between observations [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>].<disp-formula id="Equg"><alternatives><tex-math id="d33e1359">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_{{00,i,j}} = \frac{{\lambda _{{10,i}} + \lambda _{{01,i}} \cdot e^{{ - \left( {\lambda _{{10,i}} + \lambda _{{01,i}} } \right)\;t_{{i,j}} }} }}{{\lambda _{{01,i}} + \lambda _{{10,i}} }}$$\end{document}</tex-math><mml:math id="d33e1364" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>00</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.277778em"/><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equg.gif"/></alternatives></disp-formula><disp-formula id="Equh"><alternatives><tex-math id="d33e1432">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{01,i,j}=1-{P}_{00,i,j}$$\end{document}</tex-math><mml:math id="d33e1437" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>00</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equh.gif"/></alternatives></disp-formula><disp-formula id="Equi"><alternatives><tex-math id="d33e1459">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_{{11,i,j}} = \frac{{\lambda _{{01,i}} + ~\lambda _{{10,i}} \cdot e^{{ - \left( {\lambda _{{10,i}} + \lambda _{{01,i}} } \right)\;t_{{i,j}} }} }}{{\lambda _{{01,i}} + \lambda _{{10,i}} }}$$\end{document}</tex-math><mml:math id="d33e1464" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mspace width="3.33333pt"/><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.277778em"/><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equi.gif"/></alternatives></disp-formula><disp-formula id="Equj"><alternatives><tex-math id="d33e1533">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{10,i,j}=1-{P}_{11,i,j}$$\end{document}</tex-math><mml:math id="d33e1538" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equj.gif"/></alternatives></disp-formula></p><p id="Par22">Here, <inline-formula id="IEq45"><alternatives><tex-math id="d33e1562">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01,i}$$\end{document}</tex-math><mml:math id="d33e1567"><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq45.gif"/></alternatives></inline-formula> is the transfer rate constant from state 0 to state 1 in individual <inline-formula id="IEq46"><alternatives><tex-math id="d33e1576">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1581"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, <inline-formula id="IEq47"><alternatives><tex-math id="d33e1585">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10,i}$$\end{document}</tex-math><mml:math id="d33e1590"><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq47.gif"/></alternatives></inline-formula> is the transfer rate constant from state 1 to state 0 in individual <inline-formula id="IEq48"><alternatives><tex-math id="d33e1599">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1604"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq49"><alternatives><tex-math id="d33e1608">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\Delta t}_{i,j}$$\end{document}</tex-math><mml:math id="d33e1613"><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq49.gif"/></alternatives></inline-formula> is the time difference between the current and previous observations in individual <inline-formula id="IEq50"><alternatives><tex-math id="d33e1626">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1631"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at observation occasion <inline-formula id="IEq51"><alternatives><tex-math id="d33e1635">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="d33e1640"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq19.gif"/></alternatives></inline-formula>. Other parameters are as previously defined. Treatment and covariate effects can be applied to <inline-formula id="IEq52"><alternatives><tex-math id="d33e1644">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e1649"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> and <inline-formula id="IEq53"><alternatives><tex-math id="d33e1655">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e1660"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>.</p><p id="Par23">In the current case, the CTMM was implemented as ordinary differential equations (ODEs) representing the probabilities of ADA being negative or positive (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>):<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Structure of the continuous-time Markov model (CTMM). <inline-formula id="IEq148"><alternatives><tex-math id="d33e1677">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e1682"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>: rate constant for ADA+&#8201;to ADA&#8722; transition; <inline-formula id="IEq149"><alternatives><tex-math id="d33e1688">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e1693"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>: rate constant for ADA&#8722; to ADA+&#8201;transition; <inline-formula id="IEq150"><alternatives><tex-math id="d33e1699">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A1$$\end{document}</tex-math><mml:math id="d33e1704"><mml:mrow><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq150.gif"/></alternatives></inline-formula>: probability for ADA+&#8201;; <inline-formula id="IEq151"><alternatives><tex-math id="d33e1710">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A0$$\end{document}</tex-math><mml:math id="d33e1715"><mml:mrow><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq151.gif"/></alternatives></inline-formula>: probability for ADA&#8722;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig3_HTML.jpg"/></fig><disp-formula id="Equk"><alternatives><tex-math id="d33e1723">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{A}_{0}}{dt}=-{\lambda }_{01}\cdot {A}_{0}+{\lambda }_{10}\cdot {A}_{1}$$\end{document}</tex-math><mml:math id="d33e1728" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equk.gif"/></alternatives></disp-formula><disp-formula id="Equl"><alternatives><tex-math id="d33e1757">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{A}_{1}}{dt}={\lambda }_{01}\cdot {A}_{0}-{\lambda }_{10}\cdot {A}_{1}$$\end{document}</tex-math><mml:math id="d33e1762" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mo>&#183;</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equl.gif"/></alternatives></disp-formula></p><p id="Par240"><inline-formula id="IEq540"><alternatives><tex-math id="d33e1791">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${A}_{0}$$\end{document}</tex-math><mml:math id="d33e1796"><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq540.gif"/></alternatives></inline-formula> and <inline-formula id="IEq550"><alternatives><tex-math id="d33e1802">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${A}_{1}$$\end{document}</tex-math><mml:math id="d33e1807"><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq550.gif"/></alternatives></inline-formula> represent the probabilities of ADA being negative and positive, respectively. Using this approach, modifications to the data file were necessary to facilitate analysis with NONMEM (version 7.4.3) [<xref ref-type="bibr" rid="CR19">19</xref>]; compartment amounts and associated bioavailability values were reset after each observation [<xref ref-type="bibr" rid="CR18">18</xref>]. Aside from ADA status itself, covariates on ADA state transition probabilities were considered, particularly tumor type. The transition rates were estimated using a log transformation:<disp-formula id="Equz"><alternatives><tex-math id="d33e1819">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01,i}={exp}^{(log{TV}_{{\lambda }_{01}}+ {\eta }_{{\lambda}_{01})}}$$\end{document}</tex-math><mml:math id="d33e1824" display="block"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="italic">TV</mml:mi></mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equz.gif"/></alternatives></disp-formula></p><p id="Par24"><inline-formula id="IEq54"><alternatives><tex-math id="d33e1862">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${A}_{0}$$\end{document}</tex-math><mml:math id="d33e1867"><mml:msub><mml:mi>A</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq540.gif"/></alternatives></inline-formula> and <inline-formula id="IEq55"><alternatives><tex-math id="d33e1873">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${A}_{1}$$\end{document}</tex-math><mml:math id="d33e1878"><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq550.gif"/></alternatives></inline-formula> represent the probabilities of ADA being negative and positive, respectively. Using this approach, modifications to the data file were necessary to facilitate analysis with NONMEM (version 7.4.3) [<xref ref-type="bibr" rid="CR19">19</xref>]; compartment amounts and associated bioavailability values were reset after each observation [<xref ref-type="bibr" rid="CR18">18</xref>]. Aside from ADA status itself, covariates on ADA state transition probabilities were considered, particularly tumor type. The transition rates were estimated using a log transformation:<disp-formula id="Equm"><alternatives><tex-math id="d33e1890">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01,i}={exp}^{(log{TV}_{{\lambda }_{01}}+ {{\eta }_{\lambda }}_{01})}$$\end{document}</tex-math><mml:math id="d33e1895" display="block"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="italic">TV</mml:mi></mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>&#955;</mml:mi></mml:msub></mml:mrow><mml:mn>01</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equm.gif"/></alternatives></disp-formula></p><p id="Par25">Here, <inline-formula id="IEq56"><alternatives><tex-math id="d33e1933">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01,i}$$\end{document}</tex-math><mml:math id="d33e1938"><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq45.gif"/></alternatives></inline-formula> is the individual realization of patient <inline-formula id="IEq57"><alternatives><tex-math id="d33e1947">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1952"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>&#8217;s transition rate from ADA&#8722; to ADA+&#8201;where <inline-formula id="IEq58"><alternatives><tex-math id="d33e1956">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${TV}_{{\lambda }_{01}}$$\end{document}</tex-math><mml:math id="d33e1961"><mml:msub><mml:mrow><mml:mi mathvariant="italic">TV</mml:mi></mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq58.gif"/></alternatives></inline-formula> is the typical value of the transition rate in the population and <inline-formula id="IEq59"><alternatives><tex-math id="d33e1971">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\eta }_{{\lambda}_{01}}$$\end{document}</tex-math><mml:math id="d33e1976"><mml:msub><mml:mi>&#951;</mml:mi><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq59.gif"/></alternatives></inline-formula> is the IIV defined as being normally distributed with a mean of 0 and variance of <inline-formula id="IEq60"><alternatives><tex-math id="d33e1984">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\omega }_{{\lambda }_{01}}^{2}$$\end{document}</tex-math><mml:math id="d33e1989"><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq60.gif"/></alternatives></inline-formula>.However, the data did not support the estimation of IIV in <inline-formula id="IEq61"><alternatives><tex-math id="d33e2000">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e2005"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> or <inline-formula id="IEq62"><alternatives><tex-math id="d33e2011">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}.$$\end{document}</tex-math><mml:math id="d33e2016"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq62.gif"/></alternatives></inline-formula></p><p id="Par26">The joint PK-ADA model combined the base population PK model (without ADA effect or IOV) with the final CTMM (including covariates). The models were linked by (1) estimating the correlation between avelumab clearance and <inline-formula id="IEq63"><alternatives><tex-math id="d33e2025">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e2030"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>, (2) effect of probability of ADA+&#8201;status (<inline-formula id="IEq64"><alternatives><tex-math id="d33e2036">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e2041"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula>) on clearance (mono-directional joint PK-ADA model), and (3) time-course of the effect of avelumab exposure on the <inline-formula id="IEq65"><alternatives><tex-math id="d33e2047">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e2052"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> and the effect of <inline-formula id="IEq66"><alternatives><tex-math id="d33e2058">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e2063"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula> on clearance (bi-directional joint PK-ADA model). The typical values of avelumab clearance, <inline-formula id="IEq67"><alternatives><tex-math id="d33e2069">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e2074"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>, and the associated IIV parameters were estimated. All other parameters were fixed to the final typical values of the estimates of the base population PK model and the final CTMM.</p><p id="Par27">The bi-directional effects are demonstrated in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>. The effect of <inline-formula id="IEq68"><alternatives><tex-math id="d33e2085">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e2090"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula> on avelumab CL (<inline-formula id="IEq69"><alternatives><tex-math id="d33e2096">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P1}_{eff,i}$$\end{document}</tex-math><mml:math id="d33e2101"><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq69.gif"/></alternatives></inline-formula>) was modeled as a linear or as a non-linear relationship between <inline-formula id="IEq70"><alternatives><tex-math id="d33e2114">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e2119"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula> (independent variable) and CL (dependent variable):<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Structure of the bidirectional joint PK-ADA model. CL: clearance; Q: intercompartmental clearance; V1: central volume of distribution; V2: peripheral volume of distribution; <inline-formula id="IEq152"><alternatives><tex-math id="d33e2131">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P{1}_{eff}$$\end{document}</tex-math><mml:math id="d33e2136"><mml:mrow><mml:mi>P</mml:mi><mml:msub><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="italic">eff</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq152.gif"/></alternatives></inline-formula>: effect of probability of ADA+&#8201;on CL; <inline-formula id="IEq153"><alternatives><tex-math id="d33e2146">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$C{1}_{eff}$$\end{document}</tex-math><mml:math id="d33e2151"><mml:mrow><mml:mi>C</mml:mi><mml:msub><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="italic">eff</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq153.gif"/></alternatives></inline-formula>: effect of concentration in central compartment on probability of ADA+&#8201;; <inline-formula id="IEq154"><alternatives><tex-math id="d33e2161">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${Time}_{eff}$$\end{document}</tex-math><mml:math id="d33e2166"><mml:msub><mml:mrow><mml:mi mathvariant="italic">Time</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">eff</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq154.gif"/></alternatives></inline-formula>: effect of time on CL; <inline-formula id="IEq155"><alternatives><tex-math id="d33e2176">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}_{max}$$\end{document}</tex-math><mml:math id="d33e2181"><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq10.gif"/></alternatives></inline-formula>: maximum change in CL relative to baseline; <inline-formula id="IEq156"><alternatives><tex-math id="d33e2189">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${T}_{50}$$\end{document}</tex-math><mml:math id="d33e2194"><mml:msub><mml:mi>T</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq9.gif"/></alternatives></inline-formula>: time for half of maximum effect; <inline-formula id="IEq157"><alternatives><tex-math id="d33e2201">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma :$$\end{document}</tex-math><mml:math id="d33e2206"><mml:mrow><mml:mi>&#947;</mml:mi><mml:mo>:</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq157.gif"/></alternatives></inline-formula> shape of time effect curve; <inline-formula id="IEq158"><alternatives><tex-math id="d33e2212">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{\text{max}\_c1}$$\end{document}</tex-math><mml:math id="d33e2217"><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq158.gif"/></alternatives></inline-formula>: maximum change in effect of exposure on rate of transition from ADA&#8722; to ADA+&#8201;; <inline-formula id="IEq159"><alternatives><tex-math id="d33e2227">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${EC}_{50}$$\end{document}</tex-math><mml:math id="d33e2232"><mml:msub><mml:mrow><mml:mi mathvariant="italic">EC</mml:mi></mml:mrow><mml:mn>50</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq159.gif"/></alternatives></inline-formula>: concentration for half of maximum exposure effect; <inline-formula id="IEq160"><alternatives><tex-math id="d33e2240">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\gamma }_{c1}$$\end{document}</tex-math><mml:math id="d33e2245"><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq160.gif"/></alternatives></inline-formula>: shape of exposure effect curve; <inline-formula id="IEq161"><alternatives><tex-math id="d33e2253">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{\text{max}\_p1}$$\end{document}</tex-math><mml:math id="d33e2258"><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq161.gif"/></alternatives></inline-formula>: maximum change in CL due to ADA; <inline-formula id="IEq162"><alternatives><tex-math id="d33e2268">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${EP1}_{50}$$\end{document}</tex-math><mml:math id="d33e2273"><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mn>50</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq162.gif"/></alternatives></inline-formula>: probability of ADA+&#8201;for half of maximum ADA effect; <inline-formula id="IEq163"><alternatives><tex-math id="d33e2283">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\gamma }_{p1}$$\end{document}</tex-math><mml:math id="d33e2288"><mml:msub><mml:mi>&#947;</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq163.gif"/></alternatives></inline-formula>: shape of the ADA effect curve; <inline-formula id="IEq164"><alternatives><tex-math id="d33e2296">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e2301"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>: rate constant for ADA+&#8201;to ADA&#8722; transition; <inline-formula id="IEq165"><alternatives><tex-math id="d33e2307">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e2312"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>: rate constant for ADA&#8722; to ADA+&#8201;transition; <inline-formula id="IEq166"><alternatives><tex-math id="d33e2318">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e2323"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula>: probability for ADA+&#8201;; <inline-formula id="IEq167"><alternatives><tex-math id="d33e2329">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p0$$\end{document}</tex-math><mml:math id="d33e2334"><mml:mrow><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq167.gif"/></alternatives></inline-formula>: probability for ADA&#8722;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig4_HTML.jpg"/></fig><disp-formula id="Equn"><alternatives><tex-math id="d33e2342">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${k}_{10,i}=\frac{{CL}_{i}}{{V1}_{i}}\cdot {P1}_{eff,i}\cdot {e}^{{(Time}_{eff}+{\eta }_{CL,i})}$$\end{document}</tex-math><mml:math id="d33e2347" display="block"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>T</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">eff</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equn.gif"/></alternatives></disp-formula><disp-formula id="Equo"><alternatives><tex-math id="d33e2407">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P1}_{eff,i}=1+sl\cdot {p1}_{i} (\text{linear model})$$\end{document}</tex-math><mml:math id="d33e2412" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mo>&#183;</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>linear model</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equo.gif"/></alternatives></disp-formula><disp-formula id="Equp"><alternatives><tex-math id="d33e2442">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P1}_{eff,i}=1+\frac{{E}_{\text{max}\_P1 }\cdot {p1}_{t,i}^{{\gamma }_{P1}}}{{EP}_{50}^{{\gamma }_{P1}}+{p1}_{t,i}^{{\gamma }_{P1}}} (\text{non-linear model})$$\end{document}</tex-math><mml:math id="d33e2447" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="italic">EP</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>non-linear model</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equp.gif"/></alternatives></disp-formula></p><p id="Par28">Here, <inline-formula id="IEq71"><alternatives><tex-math id="d33e2520">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${k}_{10,i}$$\end{document}</tex-math><mml:math id="d33e2525"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq71.gif"/></alternatives></inline-formula>, <inline-formula id="IEq72"><alternatives><tex-math id="d33e2534">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${CL}_{i}$$\end{document}</tex-math><mml:math id="d33e2539"><mml:msub><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq72.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq73"><alternatives><tex-math id="d33e2547">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${V1}_{i}$$\end{document}</tex-math><mml:math id="d33e2552"><mml:msub><mml:mrow><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq73.gif"/></alternatives></inline-formula> are the avelumab elimination rate constant from the central compartment, avelumab CL, and central volume of distribution, respectively, for patient <inline-formula id="IEq74"><alternatives><tex-math id="d33e2560">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e2565"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>. In the linear model the intercept is set to 1 (no change) and <inline-formula id="IEq75"><alternatives><tex-math id="d33e2569">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$sl$$\end{document}</tex-math><mml:math id="d33e2574"><mml:mrow><mml:mi mathvariant="italic">sl</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq75.gif"/></alternatives></inline-formula> is the slope of change in <inline-formula id="IEq76"><alternatives><tex-math id="d33e2581">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1.$$\end{document}</tex-math><mml:math id="d33e2586"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq76.gif"/></alternatives></inline-formula> The nonlinear model is a sigmoidal Emax model, and <inline-formula id="IEq77"><alternatives><tex-math id="d33e2593">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{\text{max}\_P1}$$\end{document}</tex-math><mml:math id="d33e2598"><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq77.gif"/></alternatives></inline-formula> and <inline-formula id="IEq78"><alternatives><tex-math id="d33e2608">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${EP}_{50}$$\end{document}</tex-math><mml:math id="d33e2613"><mml:msub><mml:mrow><mml:mi mathvariant="italic">EP</mml:mi></mml:mrow><mml:mn>50</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq78.gif"/></alternatives></inline-formula> are the maximum effect and 50% of the maximum effect of <inline-formula id="IEq79"><alternatives><tex-math id="d33e2621">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e2626"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula> on clearance. <inline-formula id="IEq80"><alternatives><tex-math id="d33e2632">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\gamma }^{CP1}$$\end{document}</tex-math><mml:math id="d33e2637"><mml:msup><mml:mrow><mml:mi>&#947;</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq80.gif"/></alternatives></inline-formula> describes the shape of the relationship.</p><p id="Par29">The link model for the relationship between exposure and rate of ADA transition (<inline-formula id="IEq81"><alternatives><tex-math id="d33e2649">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${C1}_{eff}$$\end{document}</tex-math><mml:math id="d33e2654"><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">eff</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq81.gif"/></alternatives></inline-formula>) is a sigmoidal Emax model:<disp-formula id="Equq"><alternatives><tex-math id="d33e2664">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01,i}={e}^{({C1}_{eff,i}\bullet log{\theta }_{\lambda 01}+{\eta }_{\lambda 01})}$$\end{document}</tex-math><mml:math id="d33e2669" display="block"><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equq.gif"/></alternatives></disp-formula><disp-formula id="Equr"><alternatives><tex-math id="d33e2712">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${C1}_{eff,i}=1+\frac{{E}_{\text{max}\_C1\bullet {C1}_{t,i}^{{\gamma }_{C1}}}}{{EC}_{50}^{{\gamma }_{C1}}+{C1}_{t,i}^{{\gamma }_{C1}}}$$\end{document}</tex-math><mml:math id="d33e2717" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>C</mml:mi><mml:mn>1</mml:mn><mml:mo>&#8729;</mml:mo><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:msub><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="italic">EC</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equr.gif"/></alternatives></disp-formula></p><p id="Par30">Here, <inline-formula id="IEq82"><alternatives><tex-math id="d33e2784">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${C1}_{t,i}$$\end{document}</tex-math><mml:math id="d33e2789"><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq82.gif"/></alternatives></inline-formula> is avelumab concentration in the central compartment in individual <inline-formula id="IEq83"><alternatives><tex-math id="d33e2800">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e2805"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula> at time <inline-formula id="IEq84"><alternatives><tex-math id="d33e2809">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="d33e2814"><mml:mi>t</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq3.gif"/></alternatives></inline-formula>, <inline-formula id="IEq85"><alternatives><tex-math id="d33e2818">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{\text{max}\_C1\bullet }$$\end{document}</tex-math><mml:math id="d33e2823"><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>C</mml:mi><mml:mn>1</mml:mn><mml:mo>&#8729;</mml:mo></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq85.gif"/></alternatives></inline-formula> is the typical value of the maximal possible change in <inline-formula id="IEq86"><alternatives><tex-math id="d33e2834">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e2839"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> relative to baseline, <inline-formula id="IEq87"><alternatives><tex-math id="d33e2846">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${EC}_{50}$$\end{document}</tex-math><mml:math id="d33e2851"><mml:msub><mml:mrow><mml:mi mathvariant="italic">EC</mml:mi></mml:mrow><mml:mn>50</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq159.gif"/></alternatives></inline-formula> is the typical value of the concentration at which 50% of <inline-formula id="IEq88"><alternatives><tex-math id="d33e2859">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{\text{max}\_C1\bullet }$$\end{document}</tex-math><mml:math id="d33e2864"><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mtext>max</mml:mtext><mml:mi>_</mml:mi><mml:mi>C</mml:mi><mml:mn>1</mml:mn><mml:mo>&#8729;</mml:mo></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq85.gif"/></alternatives></inline-formula> is reached, and <inline-formula id="IEq89"><alternatives><tex-math id="d33e2875">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\gamma }^{C1}$$\end{document}</tex-math><mml:math id="d33e2880"><mml:msup><mml:mrow><mml:mi>&#947;</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq89.gif"/></alternatives></inline-formula> describes the shape of the relationship. The direction of the maximum change (i.e. an increase or a decrease) was not specified but was limited to a range of &#8722;&#160;100% to 500%.</p></sec><sec id="Sec8"><title>Covariate model</title><p id="Par31">Potential covariate relationships were explored graphically by plotting the potential covariates versus the parameters of interest. Graphical exploration procedures were only relied upon if the degree of &#951;-shrinkage in the parameters was reasonably low (&lt;&#8201;30%) [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par32">Covariate analysis for the population PK model was restricted to the relationship between the different categorizations of ADA status (ADAEVER, ADAONE, ADALOCF, etc.) and avelumab CL. The ADA-CL relationship was implemented using a linear function:<disp-formula id="Equs"><alternatives><tex-math id="d33e2898">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${CL}_{i}=TVCL\cdot \left(1+{\theta }_{ADA}\right)$$\end{document}</tex-math><mml:math id="d33e2903" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:mi>V</mml:mi><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>&#183;</mml:mo><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ADA</mml:mi></mml:mrow></mml:msub></mml:mfenced></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equs.gif"/></alternatives></disp-formula></p><p id="Par33">Here, <inline-formula id="IEq90"><alternatives><tex-math id="d33e2927">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${CL}_{i}$$\end{document}</tex-math><mml:math id="d33e2932"><mml:msub><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq72.gif"/></alternatives></inline-formula> is CL in individual <inline-formula id="IEq91"><alternatives><tex-math id="d33e2940">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e2945"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, <inline-formula id="IEq92"><alternatives><tex-math id="d33e2949">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$TVCL$$\end{document}</tex-math><mml:math id="d33e2954"><mml:mrow><mml:mi mathvariant="italic">TVCL</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq4.gif"/></alternatives></inline-formula> is the typical value of CL in the population, and <inline-formula id="IEq93"><alternatives><tex-math id="d33e2960">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\theta }_{ADA}$$\end{document}</tex-math><mml:math id="d33e2965"><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ADA</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq93.gif"/></alternatives></inline-formula> is the estimated of change in CL when ADA+&#8201;. For the DTMM and CTMM, covariate relationships included demographics (age, sex, and race), disease-related status (serum albumin, C-reactive protein [CRP], Eastern Cooperative Oncology Group performance score [ECOG] status, tumor type, and baseline tumor burden), previous and current concomitant therapies (previous use of biologics or PD-L1 inhibitors), and baseline laboratory results and organ function (aspartate transaminase [AST], alanine transaminase [ALT], creatinine, creatinine clearance, bilirubin, estimated glomerular filtration rate [eGFR]). Categorical covariates were tested using a linear function and continuous covariates were tested using power functions (see below).</p><p id="Par34">Covariate model development was performed stepwise (using the stepwise covariate modeling tool in Perl-speaks-NONMEM [PsN], version 5.3.0) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Each candidate covariate was tested on each of the parameters of interest, one at a time. The parameter-covariate relationship producing the largest change in the NONMEM objective function value (OFV) was retained. This process was repeated as a series of forward model-building steps until no further parameter-covariate relationships were present that met the forward inclusion criterion (a change in OFV of &#8722;&#160;3.843, corresponding to a nominal significance level of p&#8201;=&#8201;0.05). A backward elimination process was then undertaken, in which each relationship was removed one at a time. At each backward step, the parameter-covariate relationship with the lowest change in OFV and not meeting the backward elimination criterion (a change in OFV of&#8201;+&#8201;10.83, corresponding to a nominal significance level of p&#8201;=&#8201;0.001) was removed. The process was concluded when no further parameter-covariate relationships could be removed.</p><p id="Par35">The testing of categorical covariates was implemented using a linear function, as follows:<disp-formula id="Equt"><alternatives><tex-math id="d33e2983">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PARCOV}_{i}={PAR}_{i}\cdot \left(1+{\theta }_{PAR,COV,val}\right)$$\end{document}</tex-math><mml:math id="d33e2988" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">PARCOV</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">PAR</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>&#183;</mml:mo><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mfenced></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equt.gif"/></alternatives></disp-formula>where <inline-formula id="IEq94"><alternatives><tex-math id="d33e3021">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PARCOV}_{i}$$\end{document}</tex-math><mml:math id="d33e3026"><mml:msub><mml:mrow><mml:mi mathvariant="italic">PARCOV</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq94.gif"/></alternatives></inline-formula> is the parameter value for individual <inline-formula id="IEq95"><alternatives><tex-math id="d33e3034">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e3039"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, <inline-formula id="IEq96"><alternatives><tex-math id="d33e3043">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PAR}_{i}$$\end{document}</tex-math><mml:math id="d33e3048"><mml:msub><mml:mrow><mml:mi mathvariant="italic">PAR</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq96.gif"/></alternatives></inline-formula> is the typical value of the parameter in the population, and <inline-formula id="IEq97"><alternatives><tex-math id="d33e3056">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\theta }_{PAR,COV,val}$$\end{document}</tex-math><mml:math id="d33e3061"><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq97.gif"/></alternatives></inline-formula> is an estimated parameter corresponding to the unique value of the categorical covariate in individual <inline-formula id="IEq98"><alternatives><tex-math id="d33e3079">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e3084"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>. For the largest or reference category,&#160;<inline-formula id="IEq99"><alternatives><tex-math id="d33e3088">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\theta }_{PAR,COV}$$\end{document}</tex-math><mml:math id="d33e3093"><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq99.gif"/></alternatives></inline-formula> was defined as 0. Covariate categories containing less than 20 patients were not separately tested (except for tumor type) but instead lumped with the reference case (typically the category with highest frequency in the population).</p><p id="Par36">Testing of continuous covariates was performed using a power function, as follows:<disp-formula id="Equu"><alternatives><tex-math id="d33e3108">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PARCOV}_{i}={PAR}_{i}\cdot {\left(\frac{{COV}_{i}}{\overline{COV} }\right)}^{{\theta }_{PAR,COV}}$$\end{document}</tex-math><mml:math id="d33e3113" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">PARCOV</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">PAR</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>&#183;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="italic">COV</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mover><mml:mrow><mml:mi mathvariant="italic">COV</mml:mi></mml:mrow><mml:mo>&#175;</mml:mo></mml:mover></mml:mfrac></mml:mfenced></mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10928_2025_9971_Article_Equu.gif"/></alternatives></disp-formula>where <inline-formula id="IEq100"><alternatives><tex-math id="d33e3153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PARCOV}_{i}$$\end{document}</tex-math><mml:math id="d33e3158"><mml:msub><mml:mrow><mml:mi mathvariant="italic">PARCOV</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq94.gif"/></alternatives></inline-formula> and <inline-formula id="IEq101"><alternatives><tex-math id="d33e3166">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PAR}_{i}$$\end{document}</tex-math><mml:math id="d33e3171"><mml:msub><mml:mrow><mml:mi mathvariant="italic">PAR</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq96.gif"/></alternatives></inline-formula> are as previously defined, <inline-formula id="IEq102"><alternatives><tex-math id="d33e3179">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${COV}_{i}$$\end{document}</tex-math><mml:math id="d33e3184"><mml:msub><mml:mrow><mml:mi mathvariant="italic">COV</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq102.gif"/></alternatives></inline-formula> is the value of the covariate in individual <inline-formula id="IEq103"><alternatives><tex-math id="d33e3192">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e3197"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq2.gif"/></alternatives></inline-formula>, <inline-formula id="IEq104"><alternatives><tex-math id="d33e3202">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\overline{COV }$$\end{document}</tex-math><mml:math id="d33e3207"><mml:mover><mml:mrow><mml:mi mathvariant="italic">COV</mml:mi></mml:mrow><mml:mo>&#175;</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq104.gif"/></alternatives></inline-formula> is the median value of the covariate in the population, and <inline-formula id="IEq105"><alternatives><tex-math id="d33e3215">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\theta }_{PAR,COV}$$\end{document}</tex-math><mml:math id="d33e3220"><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq99.gif"/></alternatives></inline-formula> is a parameter describing the shape of the relationship of the covariate to the parameter.</p></sec><sec id="Sec9"><title>Model evaluation and qualification</title><p id="Par37">Stratification was used when appropriate to ensure that the model could be evaluated adequately across important subgroups of the data. The adequacy of the models was evaluated using visual predictive checks (VPC) [<xref ref-type="bibr" rid="CR23">23</xref>]. The population PK and PK-ADA models were used to simulate 500 replicates (model development) or 1000 replicates (external validation) of the analysis data set. Statistics of interest were calculated from the simulated and observed data for comparison: the 2.5th, 50th (median), and 97.5th percentiles of the distributions of the simulated concentration at each sampling time bin were calculated. These percentiles of the simulated data were plotted versus time, with the original observed data set and/or percentiles based on the observed data overlaid to visually assess concordance between the model-based simulated data and the observed data.</p><p id="Par38">Final models were used to predict dependent variables (avelumab concentrations and/or ADA data) based on the patients in the data&#160;set who were&#160;set aside for external validation (20% of the data set) at the individual and population level (the latter using VPCs). These were compared with observations to provide an assessment of the model&#8217;s predictive ability.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Population PK models with ADA as time-invariant or time-varying covariate on clearance</title><p id="Par39">The increase in avelumab CL attributable to ADA+&#8201;status ranged from 8.5% (time-varying model using the time-course of ADA status to influence CL) to 19.9% (time-invariant model with inter-occasion variability [IOV] in CL). The IOV in CL (4%) was negligible compared with inter-individual variability (IIV) in CL (34%), and the inclusion of IOV did not change the estimates of IIV. Simulation-based evaluations (VPCs) confirmed that predictive performance of the PK models was acceptable. The results of the effects of ADA on avelumab CL and the associated computation burden (relative estimation time) are summarized in Table <xref rid="Tab2" ref-type="table">2</xref>. The parameter estimates for each model (Table 7) and the goodness of fit plots for the population PK model (Fig. 9)&#160;are provided in the supplementary material.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary of effect of ADA status on avelumab CL conditioned on the modeling approach</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Model Type</th><th align="left" colspan="1" rowspan="1">Covariate Relationship with TVCL</th><th align="left" colspan="1" rowspan="1">Time-variant Relationship</th><th align="left" colspan="1" rowspan="1">Estimated Increase in CL (%) for ADA+&#8201;</th><th align="left" colspan="1" rowspan="1">TVCL (L/h)</th><th align="left" colspan="1" rowspan="1">CL ADA&#8722;/CL ADA+&#8201;(L/h)</th><th align="left" colspan="1" rowspan="1">Data Set Modification</th><th align="left" colspan="1" rowspan="1">Computational Burden*</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">PPK without IOV in CL</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">0.0285</td><td align="left" colspan="1" rowspan="1">0.0283/0.0332</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Separate TVCL</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">0.0279/0.335</td><td align="left" colspan="1" rowspan="1">0.0282/0.0339</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Low</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ADAEVER</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">19.0</td><td align="left" colspan="1" rowspan="1">0.0279</td><td align="left" colspan="1" rowspan="1">0.0282/0.0339</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Low</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ADAONCE</td><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">10.6</td><td align="left" colspan="1" rowspan="1">0.0283</td><td align="left" colspan="1" rowspan="1">0.0282/0.0344</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Low</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ADALOCF</td><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">8.5</td><td align="left" colspan="1" rowspan="1">0.0285</td><td align="left" colspan="1" rowspan="1">0.0293/0.0314</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Low</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ADALOCF</td><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="8" rowspan="1">PPK with IOV in CL</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">0.0285</td><td align="left" colspan="1" rowspan="1">0.0289/0.0342</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">High</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ADAEVER</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">19.9</td><td align="left" colspan="1" rowspan="1">0.0285</td><td align="left" colspan="1" rowspan="1">0.0280/0.0335</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">High</td></tr><tr><td align="left" colspan="8" rowspan="1">Joint ADA/PK model</td></tr><tr><td align="left" colspan="1" rowspan="1">Mono-directional</td><td align="left" colspan="1" rowspan="1">Probability of ADA+&#8201;</td><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">14.9</td><td align="left" colspan="1" rowspan="1">0.0285 <italic toggle="yes">fix</italic></td><td align="left" colspan="1" rowspan="1">0.0261/0.0317</td><td align="left" colspan="1" rowspan="1">Substantial</td><td align="left" colspan="1" rowspan="1">High</td></tr><tr><td align="left" colspan="1" rowspan="1">Bi-directional</td><td align="left" colspan="1" rowspan="1">Probability of ADA+&#8201;</td><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">11.6</td><td align="left" colspan="1" rowspan="1">0.0285 <italic toggle="yes">fix</italic></td><td align="left" colspan="1" rowspan="1">0.0258/0.0313</td><td align="left" colspan="1" rowspan="1">Substantial</td><td align="left" colspan="1" rowspan="1">High</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ADAEVER</italic> time-invariant categorical covariate (0&#8201;=&#8201;&#8220;ADA&#8722;&#160;Never&#8221; or 1&#8201;=&#8201;"ADA+&#8201;: At least once&#8221;); <italic toggle="yes">ADAONCE</italic> time-variant categorial covariate, <italic toggle="yes">CL</italic> mean of individual clearance values, <italic toggle="yes">IOV</italic> inter-occasion variability (evaluation limited to the first 12 visits), <italic toggle="yes">NA</italic> not applicable, <italic toggle="yes">PPK</italic> population pharmacokinetic, <italic toggle="yes">TVCL</italic> typical population value of clearance</p><p><sup>*</sup> Computational burden relative to the base model: low: 1&#8211;4-fold increase in run times; moderate: 4&#8211;8-fold increase in run times; high:&#8201;&gt;&#8201;8-fold increase in run times</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Markov models for ADA status</title><p id="Par40">The structures of the population ADA models are provided in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> (DTMM), Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> (CTMM), and Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref> (joint PK-CTMM). In the DTMM, the probability of ADA+&#8201;or ADA&#8722; status was obtained by estimating the transition probability from ADA status at the current occasion, irrespective of the time since the previous occasion. For the CTMM, the time between occasions was considered to obtain the probability of ADA+&#8201;or ADA&#8722; status because the influence of the previous ADA status on the probability of the current ADA status typically decreases with increasing time between occasions.</p><p id="Par41">The DTMM estimated the probability of baseline ADA+&#8201;status as 2.12% (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The probability of a transition from ADA&#8722; to ADA+&#8201;(<inline-formula id="IEq106"><alternatives><tex-math id="d33e3502">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e3507"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula>) status was 0.7%. The probability of a person transitioning from ADA+&#8201;to ADA&#8722; status (<inline-formula id="IEq107"><alternatives><tex-math id="d33e3513">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p10$$\end{document}</tex-math><mml:math id="d33e3518"><mml:mrow><mml:mi>p</mml:mi><mml:mn>10</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq107.gif"/></alternatives></inline-formula>) was 25.4%. The relationship between tumor type and <inline-formula id="IEq108"><alternatives><tex-math id="d33e3524">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e3529"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula> was the only significant covariate relationship in the model. The estimate of <inline-formula id="IEq109"><alternatives><tex-math id="d33e3535">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e3540"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula> was 0.73% for NSCLC (the most common tumor type), 1.8% for GC/GEJC, 0.36% for UC, 0.35% for MCC, and 0% for other&#160;solid tumors (including lung, gastrointestinal tract, skin, breast, head and neck cancers). The tumor type relationship with <inline-formula id="IEq110"><alternatives><tex-math id="d33e3547">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e3552"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula> in the&#160;final SCM model was simplified by removing the relationships between tumor types on <inline-formula id="IEq111"><alternatives><tex-math id="d33e3558">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e3563"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula> that were not statistically significant one by one. The relationship between GC/GEJC and <inline-formula id="IEq112"><alternatives><tex-math id="d33e3569">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e3574"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula> was the only statistically significant relationship (see Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). VPCs confirmed the predictive characteristics of DTMM across tumor types. The VPCs for GC/GEJC tumors are shown in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>NONMEM parameter estimates for the discrete-time Markov models</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Base Model</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Final SCM model</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Reduced Covariate Model</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">DTMM model</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">%RSE</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">%RSE</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">%RSE</td></tr><tr><td align="left" colspan="1" rowspan="1">OFV</td><td align="left" colspan="1" rowspan="1">2517.934</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2479.973</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2485.735</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#916;OFV</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;37.961</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;32.199</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Typical value for P1 at baseline (logit scale)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;3.83</td><td align="left" colspan="1" rowspan="1">1.3%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;3.83</td><td align="left" colspan="1" rowspan="1">1.6%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;3.83</td><td align="left" colspan="1" rowspan="1">1.1%</td></tr><tr><td align="left" colspan="1" rowspan="1">Typical value for P01 (logit scale)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;4.93</td><td align="left" colspan="1" rowspan="1">4.2%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;4.91</td><td align="left" colspan="1" rowspan="1">4.5%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;5.05</td><td align="left" colspan="1" rowspan="1">4.5%</td></tr><tr><td align="left" colspan="1" rowspan="1">Typical value for P10 (logit scale)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.08</td><td align="left" colspan="1" rowspan="1">6.2%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.08</td><td align="left" colspan="1" rowspan="1">9.7%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.08</td><td align="left" colspan="1" rowspan="1">5.2%</td></tr><tr><td align="left" colspan="7" rowspan="1">Change in P01 relative to NSCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;GC/GEJC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.191</td><td align="left" colspan="1" rowspan="1">22.4%</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.215</td><td align="left" colspan="1" rowspan="1">17.1%</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;UC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.142</td><td align="left" colspan="1" rowspan="1">68%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;MCC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.157</td><td align="left" colspan="1" rowspan="1">67.5%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other&#160;solid tumors</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.971</td><td align="left" colspan="1" rowspan="1">71.9%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IIV on P1 baseline, %</td><td align="left" colspan="1" rowspan="1">7.1%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.1%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.1%*</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IIV on P01, %</td><td align="left" colspan="1" rowspan="1">186.6%</td><td align="left" colspan="1" rowspan="1">15.7%</td><td align="left" colspan="1" rowspan="1">132.1%</td><td align="left" colspan="1" rowspan="1">31.8%</td><td align="left" colspan="1" rowspan="1">129.1%</td><td align="left" colspan="1" rowspan="1">27.9%</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IIV on P10, %</td><td align="left" colspan="1" rowspan="1">7.1%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.1%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.1%*</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OFV</italic>&#160;objective function value, <italic toggle="yes">&#916;OFV</italic>&#160;change in OFV from baseline model, <italic toggle="yes">P1</italic>&#160;probability of ADA+, <italic toggle="yes">P01</italic>&#160;probability to transition from ADA&#8722; to ADA+&#8201;, <italic toggle="yes">P10</italic> probability to transition from ADA+&#8201;to ADA&#8722;, <italic toggle="yes">%RSE</italic> relative standard error (percentage), <italic toggle="yes">SCM</italic>&#160;stepwise covariate model</p><p><sup>*</sup>Indicates fixed parameters</p></table-wrap-foot></table-wrap><fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Visual predictive check for the population discrete-time Markov model. Top panel: all tumor types. Bottom panel: GC/GEJC tumors (in JAVELIN Gastric 100). The open circles show the observed fractions versus time and the shaded area shows the corresponding model-based 95% confidence interval</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig5_HTML.jpg"/></fig></p><p id="Par42">The DTMM-predicted time course for ADA+&#8201;status (<inline-formula id="IEq113"><alternatives><tex-math id="d33e3820">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e3825"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula>) was evaluated as a time-varying ADA covariate in the population PK model. This enabled a gradual change to maximal probability when switching from ADA&#8722; to ADA+&#8201;status instead of an abrupt step change as was the case with the ADAONCE (&#8220;Not yet ADA+&#8201;&#8221; or &#8220;ADA+&#8201;and thereafter&#8221;) approach (see Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). The increase in avelumab CL attributable to a transition from ADA&#8722; to ADA+&#8201;was 41% (90% PI 17%, 52%) in patients with GC/GEJC, 18% (90% PI 18%, 26%) with NSCLC, 11% (90% PI 7%, 12%) with MCC, and 11% (90% PI 7%, 13%) with UC (examples of individual patients are provided in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). However, this model did not address the immortal time bias associated with step change from ADA&#8722; to ADA+&#8201;. Although this approach differentiates the effect of ADA+&#8201;status on CL between individuals (different maximum probabilities), once an individual&#8217;s maximum probability is attained, the value remains constant. This approach may be considered a sequential ADA-PK rather than a joint model to link PK and ADA models.<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Demonstration of the time-course of probability of ADA+&#8201;and the time-invariant (ADAEVER) and time-variant (ADAONCE, ADALOCF) categorization of the ADA data for five random patients who were ADA+&#8201;at least once. The open circles show the actual ADA values. The red lines show the values for ADAEVER, the green lines are ADAONCE, and&#160;the purple lines are ADALOCF. The light blue line is MCC, gray lines are NSCLC, and the yellow line is GC/GEJC. p(ADA+) is the individual probability of ADA+&#8201;from the discrete time Markov model</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig6_HTML.jpg"/></fig></p><p id="Par43">The CTMM estimated the rate of change in ADA status (parameter estimates for the important models are provided in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). The final CTMM included the effects of baseline ADA status and tumor type on the rate constant for changing from ADA&#8722; to ADA+&#8201;(<inline-formula id="IEq114"><alternatives><tex-math id="d33e3849">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e3854"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>). This rate constant was 3.8-fold higher when patients were ADA+&#8201;at baseline. Compared to NSCLC, <inline-formula id="IEq115"><alternatives><tex-math id="d33e3860">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e3865"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> was 17% higher in patients with GC/GEJC, 37% lower with UC, 38% lower with MCC, and 99% lower with other&#160;solid tumors (there were no ADA+&#8201;patients in the model development data set). The model under-predicted the time-course of the probability of ADA status for the patients with NSCLC in the later part of study JAVELIN Lung 100. The final CTMM included the same covariate relationships as in the final DTMM: baseline ADA status and tumor type on <inline-formula id="IEq116"><alternatives><tex-math id="d33e3871">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e3876"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>. The VPCs for the final model are shown in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>NONMEM parameter estimates continuous-time Markov model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Parameter</th></tr><tr><th align="left" colspan="1" rowspan="1">CTMM Model</th><th align="left" colspan="1" rowspan="1">Base Model</th><th align="left" colspan="1" rowspan="1">%RSE</th><th align="left" colspan="1" rowspan="1">Baseline ADA+&#8201;on <inline-formula id="IEq125"><alternatives><tex-math id="d33e3913">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e3918"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula></th><th align="left" colspan="1" rowspan="1">%RSE</th><th align="left" colspan="1" rowspan="1">Final Model</th><th align="left" colspan="1" rowspan="1">%RSE</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">OFV</td><td align="left" colspan="1" rowspan="1">5452566.033</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5452534.992</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5452478.918</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#916;OFV</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;31.041</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;87.115</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Typical value for <inline-formula id="IEq126"><alternatives><tex-math id="d33e3958">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e3963"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>, /h</td><td align="left" colspan="1" rowspan="1">0.00461</td><td align="left" colspan="1" rowspan="1">18.10%</td><td align="left" colspan="1" rowspan="1">0.00446</td><td align="left" colspan="1" rowspan="1">18.10%</td><td align="left" colspan="1" rowspan="1">0.00404</td><td align="left" colspan="1" rowspan="1">20.50%</td></tr><tr><td align="left" colspan="1" rowspan="1">Typical value for <inline-formula id="IEq127"><alternatives><tex-math id="d33e3985">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e3990"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>, /h</td><td align="left" colspan="1" rowspan="1">0.139</td><td align="left" colspan="1" rowspan="1">17.60%</td><td align="left" colspan="1" rowspan="1">0.142</td><td align="left" colspan="1" rowspan="1">17.80%</td><td align="left" colspan="1" rowspan="1">0.146</td><td align="left" colspan="1" rowspan="1">17.70%</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline ADA+&#8201;: change in <inline-formula id="IEq128"><alternatives><tex-math id="d33e4012">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4017"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4.84</td><td align="left" colspan="1" rowspan="1">40.50%</td><td align="left" colspan="1" rowspan="1">4.38</td><td align="left" colspan="1" rowspan="1">42.20%</td></tr><tr><td align="left" colspan="7" rowspan="1">Change in <inline-formula id="IEq129"><alternatives><tex-math id="d33e4036">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4041"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> relative to NSCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;GC/GEJC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">30%</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;UC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.404</td><td align="left" colspan="1" rowspan="1">48%</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;MCC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.373</td><td align="left" colspan="1" rowspan="1">88.50%</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other solid tumors</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.99*</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">IIV on <inline-formula id="IEq130"><alternatives><tex-math id="d33e4094">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4099"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>, %</td><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">IIV on K21, %</td><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OFV</italic> objective function value, <italic toggle="yes">&#916;OFV</italic>&#160;change in OFV from baseline model, <inline-formula id="IEq131"><alternatives><tex-math id="d33e4135">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4140"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>&#160;transit rate constant ADA&#8722; to ADA+&#8201;, <inline-formula id="IEq132"><alternatives><tex-math id="d33e4146">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e4151"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>&#160;transit rate constant ADA+&#8201;to ADA&#8722;, <italic toggle="yes">%RSE</italic>&#160;relative standard error (percentage)</p><p><sup>*</sup>Indicates fixed parameters</p></table-wrap-foot></table-wrap><fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Visual predictive check for the final continuous-time Markov model for GC/GEJC, UC, NSCLC, and MCC. The open circles show the observed fractions versus time and the shaded area shows the corresponding model-based 95% confidence interval</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Joint PK-ADA models</title><p id="Par44">The parameter estimates for the important models are provided in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>. The time-course of <inline-formula id="IEq117"><alternatives><tex-math id="d33e4177">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e4182"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula> compared to other ADA categorizations for several randomly selected patients is shown in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>NONMEM parameter estimates joint PK and ADA models</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6" rowspan="1">Parameter</th></tr><tr><th align="left" colspan="1" rowspan="1">Joint Model</th><th align="left" colspan="1" rowspan="1">Base Model</th><th align="left" colspan="1" rowspan="1">Correlation CL, C1,&#160;<inline-formula id="IEq133"><alternatives><tex-math id="d33e4215">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4220"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula></th><th align="left" colspan="1" rowspan="1">ADA on CL</th><th align="left" colspan="1" rowspan="1">ADA on CL&#8201;+&#8201;C1 on ADA</th><th align="left" colspan="1" rowspan="1">ADA on CL (Emax)&#8201;+&#8201;C1 on ADA</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">OFV</td><td align="left" colspan="1" rowspan="1">20230779.285</td><td align="left" colspan="1" rowspan="1">20230699.696</td><td align="left" colspan="1" rowspan="1">20230703.331</td><td align="left" colspan="1" rowspan="1">20230659.164</td><td align="left" colspan="1" rowspan="1">20230709.255</td></tr><tr><td align="left" colspan="1" rowspan="1">&#916;OFV</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;79.589</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;75.954</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;120.121</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;70.03</td></tr><tr><td align="left" colspan="6" rowspan="1">Avelumab population PK model</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Clearance (CL), L/h</td><td align="left" colspan="1" rowspan="1">0.0272*</td><td align="left" colspan="1" rowspan="1">0.028</td><td align="left" colspan="1" rowspan="1">0.0272*</td><td align="left" colspan="1" rowspan="1">0.0275</td><td align="left" colspan="1" rowspan="1">0.0272*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Central volume (V1), L</td><td align="left" colspan="1" rowspan="1">3.52*</td><td align="left" colspan="1" rowspan="1">3.52*</td><td align="left" colspan="1" rowspan="1">3.52*</td><td align="left" colspan="1" rowspan="1">3.52*</td><td align="left" colspan="1" rowspan="1">3.52*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Peripheral volume, L</td><td align="left" colspan="1" rowspan="1">0.582*</td><td align="left" colspan="1" rowspan="1">0.582*</td><td align="left" colspan="1" rowspan="1">0.582*</td><td align="left" colspan="1" rowspan="1">0.582*</td><td align="left" colspan="1" rowspan="1">0.582*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Intercompartmental clearance, L/h</td><td align="left" colspan="1" rowspan="1">0.0128*</td><td align="left" colspan="1" rowspan="1">0.0128*</td><td align="left" colspan="1" rowspan="1">0.0128*</td><td align="left" colspan="1" rowspan="1">0.0128*</td><td align="left" colspan="1" rowspan="1">0.0128*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;I<sub>max</sub></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.015*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.015*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.015*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.015*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.015*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;T<sub>50</sub>, days</td><td align="left" colspan="1" rowspan="1">51.9*</td><td align="left" colspan="1" rowspan="1">51.9*</td><td align="left" colspan="1" rowspan="1">51.9*</td><td align="left" colspan="1" rowspan="1">51.9*</td><td align="left" colspan="1" rowspan="1">51.9*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#947;</td><td align="left" colspan="1" rowspan="1">2.59*</td><td align="left" colspan="1" rowspan="1">2.59*</td><td align="left" colspan="1" rowspan="1">2.59*</td><td align="left" colspan="1" rowspan="1">2.59*</td><td align="left" colspan="1" rowspan="1">2.59*</td></tr><tr><td align="left" colspan="6" rowspan="1">Continuous Markov model</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rate constant ADA&#8722; to ADA+&#8201;(<inline-formula id="IEq134"><alternatives><tex-math id="d33e4365">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4370"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>), /h</td><td align="left" colspan="1" rowspan="1">0.00404*</td><td align="left" colspan="1" rowspan="1">0.00404</td><td align="left" colspan="1" rowspan="1">0.00404*</td><td align="left" colspan="1" rowspan="1">0.00406</td><td align="left" colspan="1" rowspan="1">0.00404*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rate constant ADA+&#8201;to ADA&#8722; (<inline-formula id="IEq135"><alternatives><tex-math id="d33e4390">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e4395"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>), /h</td><td align="left" colspan="1" rowspan="1">0.146*</td><td align="left" colspan="1" rowspan="1">0.146*</td><td align="left" colspan="1" rowspan="1">0.146*</td><td align="left" colspan="1" rowspan="1">0.146*</td><td align="left" colspan="1" rowspan="1">0.146*</td></tr><tr><td align="left" colspan="6" rowspan="1"> &#160;Change in <inline-formula id="IEq136"><alternatives><tex-math id="d33e4415">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4420"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> relative to NSCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;GC/GEJC</td><td align="left" colspan="1" rowspan="1">1.17*</td><td align="left" colspan="1" rowspan="1">1.17*</td><td align="left" colspan="1" rowspan="1">1.17*</td><td align="left" colspan="1" rowspan="1">1.17*</td><td align="left" colspan="1" rowspan="1">1.17*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;UC</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.404*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.404*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.404*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.404*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.404*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;MCC</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.373*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.373*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.373*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.373*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.373*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160; Other solid tumors</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.99*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.99*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.99*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.99*</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.99*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Baseline ADA+&#8201;: change in K34</td><td align="left" colspan="1" rowspan="1">4.38*</td><td align="left" colspan="1" rowspan="1">4.38*</td><td align="left" colspan="1" rowspan="1">4.38*</td><td align="left" colspan="1" rowspan="1">4.38*</td><td align="left" colspan="1" rowspan="1">4.38*</td></tr><tr><td align="left" colspan="6" rowspan="1">&#160;Effect of ADA on CL</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Slope of ADA effect on CL</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.116</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;Maximum change</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.217</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;50% of maximum change</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.446</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;Shape of effect curve</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Effect of exposure on ADA</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;Maximum change</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.374</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.405</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;50% of maximum change</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">349</td><td align="left" colspan="1" rowspan="1">387</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#160;Shape of effect curve</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2.58</td><td align="left" colspan="1" rowspan="1">2.75</td></tr><tr><td align="left" colspan="1" rowspan="1">IIV on CL, %</td><td align="left" colspan="1" rowspan="1">38.5%</td><td align="left" colspan="1" rowspan="1">40.1%</td><td align="left" colspan="1" rowspan="1">38.5%</td><td align="left" colspan="1" rowspan="1">39.9%</td><td align="left" colspan="1" rowspan="1">46.1%</td></tr><tr><td align="left" colspan="1" rowspan="1">IIV on V1, %</td><td align="left" colspan="1" rowspan="1">23.4%</td><td align="left" colspan="1" rowspan="1">25.7%</td><td align="left" colspan="1" rowspan="1">23.4%</td><td align="left" colspan="1" rowspan="1">24.6%</td><td align="left" colspan="1" rowspan="1">24.8%</td></tr><tr><td align="left" colspan="1" rowspan="1">IIV on <inline-formula id="IEq137"><alternatives><tex-math id="d33e4600">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4605"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>, %</td><td align="left" colspan="1" rowspan="1">218.1%</td><td align="left" colspan="1" rowspan="1">226.1%</td><td align="left" colspan="1" rowspan="1">218.1%</td><td align="left" colspan="1" rowspan="1">329%</td><td align="left" colspan="1" rowspan="1">414.4%</td></tr><tr><td align="left" colspan="1" rowspan="1">IIV on <inline-formula id="IEq138"><alternatives><tex-math id="d33e4625">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e4630"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>, %</td><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">0%*</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">0%</td></tr><tr><td align="left" colspan="1" rowspan="1">IIV on TMAX, %</td><td align="left" colspan="1" rowspan="1">21.8%*</td><td align="left" colspan="1" rowspan="1">21.8%*</td><td align="left" colspan="1" rowspan="1">21.8%*</td><td align="left" colspan="1" rowspan="1">21.8%*</td><td align="left" colspan="1" rowspan="1">21.8%*</td></tr><tr><td align="left" colspan="1" rowspan="1">Proportional residual error PK (&#963;<sub>prop</sub>), %</td><td align="left" colspan="1" rowspan="1">21.1%*</td><td align="left" colspan="1" rowspan="1">21.1%*</td><td align="left" colspan="1" rowspan="1">21.1%*</td><td align="left" colspan="1" rowspan="1">21.1%*</td><td align="left" colspan="1" rowspan="1">21.1%*</td></tr><tr><td align="left" colspan="1" rowspan="1">Additive residual error PK (&#963;<sub>add</sub>), ng/mL</td><td align="left" colspan="1" rowspan="1">2378.6*</td><td align="left" colspan="1" rowspan="1">2378.6*</td><td align="left" colspan="1" rowspan="1">2378.6*</td><td align="left" colspan="1" rowspan="1">2378.6*</td><td align="left" colspan="1" rowspan="1">2378.6*</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CL</italic>&#160;clearance, <italic toggle="yes">C1</italic> avelumab concentration in central compartment, <italic toggle="yes">OFV</italic> objective function value, <italic toggle="yes">&#916;OFV</italic>&#160;change in OFV from baseline model, <inline-formula id="IEq139"><alternatives><tex-math id="d33e4706">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4711"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>&#160;transit rate constant ADA&#8722; to ADA+, <inline-formula id="IEq140"><alternatives><tex-math id="d33e4717">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{10}$$\end{document}</tex-math><mml:math id="d33e4722"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>10</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq53.gif"/></alternatives></inline-formula>&#160;transit rate constant ADA+&#8201;to ADA&#8722;, <inline-formula id="IEq141"><alternatives><tex-math id="d33e4729">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\gamma }^{P1}$$\end{document}</tex-math><mml:math id="d33e4734"><mml:msup><mml:mrow><mml:mi>&#947;</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq141.gif"/></alternatives></inline-formula>&#160;shape of the effect curve for ADA on CL; <inline-formula id="IEq142"><alternatives><tex-math id="d33e4743">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\gamma }^{C1}$$\end{document}</tex-math><mml:math id="d33e4748"><mml:msup><mml:mrow><mml:mi>&#947;</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq89.gif"/></alternatives></inline-formula>: shape of the effect curve for exposure on ADA</p><p><sup>*</sup>Indicates fixed parameters</p></table-wrap-foot></table-wrap><fig id="Fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>Demonstration of the time-course of probability of ADA+&#8201;[p(ADA+)] and the time-invariant (ADAEVER) and time-variant (ADAONCE, ADALOCF) categorization of the ADA data for five random patients who were ADA+&#8201;at least once. The open circles show the actual ADA values. The lines show the values for ADAEVER, the solid green lines are ADAONCE, and&#160;the purple dotted lines are ADALOCF. The light blue line is MCC, gray lines are NSCLC, and the yellow line is GC/GEJC</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO9" position="float" orientation="portrait" xlink:href="10928_2025_9971_Fig8_HTML.jpg"/></fig></p><p id="Par45">The relationship between <inline-formula id="IEq118"><alternatives><tex-math id="d33e4769">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e4774"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula> and CL was estimated, and the maximum increase in clearance was 11.6% and 15.0% for the mono- and bi-directional joint PK-ADA models for the linear model and 21.7% for the nonlinear model, respectively. With respect to the relationship between avelumab exposure and <inline-formula id="IEq119"><alternatives><tex-math id="d33e4780">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4785"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>, maximum decrease in <inline-formula id="IEq120"><alternatives><tex-math id="d33e4791">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4796"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula> was 37% with 50% of the maximum decrease estimated to occur at a concentration of 349 &#956;g/mL. This estimate is markedly higher than the maximum avelumab concentration for adults for the clinical dose 800&#160;mg q2w (geometric mean 256.3 &#181;g/mL [<xref ref-type="bibr" rid="CR24">24</xref>]). The relationship curve was relatively steep with &#947; of 2.58.
</p><p id="Par46">The portion of the data set not used in the model development was reserved for external validation. VPCs were performed with the parameter estimates from the model development data set. The VPCs confirmed that the PK models with ADA status as a time-varying covariate, the final DTMM, and final CTMM were all able to predict the new data with acceptable accuracy and confirmed the predictive ability of the models.</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par47">Joint models refer to models that simultaneously analyze different types of outcomes or variables [<xref ref-type="bibr" rid="CR25">25</xref>]. Bi-directional joint models are models that consider interactions of relationships in both directions between the outcomes or variables. Broadly speaking, joint modeling is the estimation of two or more statistical submodels into a single joint model. Such models provide more efficient estimates of the effects and can reduce bias in the estimates of the overall effect [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par48">We developed a joint model to describe the bi-directional effects of the probability of ADA+&#8201;status (a CTMM) on the CL of avelumab (a two-compartment disposition PK model with time-varying clearance) and the effect of the avelumab concentrations on the rate of ADA&#8722; to ADA+&#8201;transition. In this analysis both the PK and ADA models were described using ODEs, which facilitated combining the ADA and PK models. The ADA and PK models were linked by estimating the correlation in the random effects (inter-individual variability) in clearance (CL) and transition rate constant (<inline-formula id="IEq121"><alternatives><tex-math id="d33e4819">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4824"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>) and by separate link functions for the effect of ADA+&#8201;on CL (a sigmoidal Emax model) and the effect of the amount of avelumab in the central compartment on <inline-formula id="IEq122"><alternatives><tex-math id="d33e4830">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{01}$$\end{document}</tex-math><mml:math id="d33e4835"><mml:msub><mml:mi>&#955;</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq52.gif"/></alternatives></inline-formula>. Insufficient data were available to assess the impact of neutralizing antibodies.</p><p id="Par49">Joint models are computationally intensive. A stepwise approach was used, starting with the development of separate PK and ADA models, with the models with shorter runtimes explored first (population PK model without IOV, and DTMM of ADA) before developing the models that required longer (the CTMM for ADA, and the joint CTMM ADA-PK model). Both the PK and ADA CTMM were modeled using sets of ODEs, resulting in long runtimes, but this made subsequent combination of the models more straightforward (see Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par50">Effect of ADA on avelumab CL was previously estimated (using ADAEVER) as 12.3% (95%&#160;CI 7%, 18%) in a full covariate model [<xref ref-type="bibr" rid="CR11">11</xref>]. For the current analysis, the model was reduced to the base model with bodyweight as the only maintained covariate. With the reduced model the ADA effect on clearance ranged from 8.5% (ADALOCF) to 19.9% (ADAEVER with IOV in CL). The estimates of IIV on clearance or the estimates of the parameters describing the time-varying component of clearance did not appear to be influenced by different ADA categorizations.</p><p id="Par51">Modeling immunogenicity has been approached in a number of ways in the literature, most commonly by incorporating as a binary variable on CL in the covariate submodel [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Several alternative approaches have been proposed at scientific meetings, but few have been published in peer-reviewed form to date. One suggested approach, which addressed interspecies scaling of a recombinant complement factor I, used a mixture model with two populations representing the presence and absence of ADA-dependent clearance in non-human primates, and included estimation of an ADA-dependent CL and an additional CL parameter along with the time of its onset to account for the potential effects of ADA in humans [<xref ref-type="bibr" rid="CR29">29</xref>]. A more complex approach proposed by Niebecker et al. comprised modeling immune response (time of seroconversion) using an ADA surrogate [<xref ref-type="bibr" rid="CR28">28</xref>]. In another approach, a semi-mechanistic PK/PD model was developed to characterize the dynamics of ADA in cancer patients receiving the V937 oncolytic virus in monotherapy or in combination with pembrolizumab, whereby the time course of ADA was modeled using the population-pharmacokinetic parameter-and data (PPP&amp;D) approach [<xref ref-type="bibr" rid="CR30">30</xref>], in which population PK parameters are fixed, but individual PK parameters are estimated simultaneously with the ADA model based on both PK and ADA data [<xref ref-type="bibr" rid="CR31">31</xref>]. Time to event models have also been employed to describe the time to appearance of ADA [<xref ref-type="bibr" rid="CR27">27</xref>]. Therein, ADA formation, which mainly took place within 3&#160;months of starting the treatment, was predicted to be lower with higher trough concentrations, which could be achieved with the use of higher doses and/or increased dosing frequency (e.g. loading doses) [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par52">In immuno-oncology settings, during treatment with immune checkpoint inhibitors including avelumab, time-variance in CL, attributed to changes in disease status, has been observed [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Consequently, exposure&#8211;response analyses using baseline exposure metrics have been found to be more consistent with the true exposure/dose&#8211;response relationship. The use of time-invariant ADA (ADAEVER) as a binary covariate may affect the estimate of baseline CL and derived exposure metrics that may mask or confound the true exposure&#8211;response relationship. Additionally, due to the fact that the ADAEVER approach conservatively treats all time points during treatment as being ADA+, bias is introduced in estimation of the effect of immunogenicity on CL, questioning the accuracy of estimates of ADA effect on PK. The estimated time to reach 50% of the maximum change in CL was consistent for all ADA covariate models (around 12&#160;months after starting treatment). During this period the DTMM demonstrated that the probability of remaining ADA&#8722; decreased rapidly (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>), again demonstrating the importance of unbiased estimates of baseline CL for exposure&#8211;response analyses. The estimation of IOV in a&#160;large data&#160;set with a long period of observation is cumbersome and drastically increases the computational burden (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>), as well as introducing significant additional complexity when using models for simulation. Assessment of IOV should be performed early during the development program to ensure that the clinical importance of the observed heterogeneity in the mechanisms and outcomes is understood prior to analyzing data from pooled studies or studies with long duration. In this analysis, the IOV over the first 12 visits was investigated, due to the large number of visits in study JAVELIN Lung 100. The first 12 visits covered a period of ca. 3&#160;years (168&#160;weeks, range 148 to 198&#160;weeks) and provided adequate coverage of the observed ADA transitions. The addition of IOV in CL did not change the estimate of the ADA effect on CL: across the models the increase in CL due to ADA using a time-invariant covariant was 20%. The estimate of IOV in CL was 4% across all models and thus negligible compared to the estimate of IIV in CL of 34%. Thus, IOV was not incorporated in the final joint PK-ADA models.</p><p id="Par53">Markov models have previously been used to analyze ADA dynamics. Hidden Markov (HM) models were developed for satralizumab, a humanized IgG2 monoclonal recycling IL-6 receptor antagonist for treatment of neuromyelitis [<xref ref-type="bibr" rid="CR34">34</xref>], and certolizumab pegol, a PEGylated Fc-free TNF&#160;inhibitor for treatment of chronic inflammatory diseases [<xref ref-type="bibr" rid="CR35">35</xref>]. A HM model is a class of probabilistic models that connect observable variables (e.g. ADA+&#8201;or ADA&#8722;) to hidden underlying states (immunological response) where the next state depends on the previous state [<xref ref-type="bibr" rid="CR34">34</xref>]. The probabilities of the observed ADA-state to the hidden immunological state were modeled as continuous random variables that could be correlated through a bivariate Gaussian probability density function [<xref ref-type="bibr" rid="CR35">35</xref>]. The HM ADA models assumed that all patients started in a state of no ADA production, and only the probabilities of transition were estimated. The stationary probabilities (ADA&#8722; transition to ADA&#8722;, and ADA+&#8201;transition to ADA+) were not estimated. The HM model for certolizumab pegol suggested that ADA are formed earlier than assays can detect. In the analysis of ADA data for avelumab, DTMM estimated that 2.2% of patients were positive at baseline, and baseline ADA+&#8201;status was a covariate in the DTMM and CTMM models. Although this estimate is in agreement with the incidence of positive baseline ADAs in clinical trials (range 1% to 20%) [<xref ref-type="bibr" rid="CR36">36</xref>], the covariate was estimated with high uncertainty in the CTMM, indicating that caution is needed when interpreting transition rates in patients with positive baseline ADA measurements. As estimating the stationary probability (ADA+&#8201;transition to ADA+) was required, the HM model as implemented for certolizumab pegol was not considered appropriate for the current analysis.</p><p id="Par54">In the DTMM, the probability of a transition from ADA&#8722; to ADA+&#8201;(<inline-formula id="IEq123"><alternatives><tex-math id="d33e4914">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p01$$\end{document}</tex-math><mml:math id="d33e4919"><mml:mrow><mml:mi>p</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq106.gif"/></alternatives></inline-formula>) status was 0.7% whereas the probability of a patient transitioning from ADA+&#8201;to ADA&#8722; status (<inline-formula id="IEq124"><alternatives><tex-math id="d33e4925">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p10$$\end{document}</tex-math><mml:math id="d33e4930"><mml:mrow><mml:mi>p</mml:mi><mml:mn>10</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq107.gif"/></alternatives></inline-formula>) was 25.4%. This difference may reflect the natural decline in antibody levels due to a diminished immune response or immune tolerance, treatment interventions (such as immunosuppressive therapies), or variability in sensitivity and specificity in assays used to detect ADA [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par55">The bidirectional joint PK-ADA model we developed for avelumab suggested that higher avelumab concentrations resulted in a decrease in transition rate to the ADA+&#8201;state. This finding is in line with the previous analyses [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], including application of HM models, which have indeed proposed that increased drug exposure reduces immunogenicity, although such findings in oncology are somewhat conflicting [<xref ref-type="bibr" rid="CR38">38</xref>]. Differences in ADA rates among tumor types have previously been reported for another immune checkpoint inhibitor, pembrolizumab, although the ADA incidence was overall low [<xref ref-type="bibr" rid="CR39">39</xref>]. In addition, there was high uncertainty in the estimates of the differences between tumor types (%RSE&#8201;&gt;&#8201;30%), indicating that the data set did not contain adequate information and should be interpreted with caution. A pooled analysis of 12 atezolizumab clinical trials did not identify meaningful differences in ADA incidence between tumor types [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par56">We have proposed considerations and utility of the population PK, ADA, and joint PK-ADA models (Table&#160;<xref rid="Tab6" ref-type="table">6</xref>). There is a fine balance between the information gained and resources required to do so. All three approaches were successful in providing quantitative insight into the relationship between avelumab exposure and ADA formation. Accounting for the phase of development, data available, and clinical need to understand the relationship between ADA dynamics and drug exposure, efficacy and/or safety can help guide the choice of the type of analysis most appropriate.<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table&#160;6</label><caption><p>Considerations and utility of the population PK, ADA, and joint PK-ADA models</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Considerations</th><th align="left" colspan="1" rowspan="1">Utility</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Population PK with IOV in clearance</td><td align="left" colspan="1" rowspan="1">The clinical relevance of the ADA effect on PK may not yet be fully characterized in early phases of clinical drug development. However, the assessment of IOV to gauge changes in variability in clearance (not specifically related to ADA) over time could be performed with data from well-controlled phase 1/2 studies in which rich PK are collected (compared with sparse PK data in phase 3/confirmatory trials). Depending on the complexity of the population PK model, the large number of occasions (study visits) in longer trials may prohibit the use of the IOV model for covariate evaluations due to high computational burden</td><td align="left" colspan="1" rowspan="1"><p>Evaluation of the parameters (random effects) associated with IOV at each occasion may indicate trends in PK parameters (clearance) with time that could be attributable to ADA effects</p><p>Evaluation of changes in time-dependent PK parameters when IOV is included, and potential confounding when estimating ADA-PK relationships</p><p>Exploratory (graphical) analysis of the random effect values to evaluate potential covariate relationships (e.g. tumor type)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Population PK with IOV and ADA covariate relationships</td><td align="left" colspan="1" rowspan="1"><p>Maintain IOV in the model if computationally feasible and/or clinically important (e.g. narrow therapeutic window)</p><p>Assess ADA&#160;relationship with important PK parameters (clearance)</p><p>If ADA status is related to adverse events, time-varying models should be considered for longitudinal assessment of safety</p></td><td align="left" colspan="1" rowspan="1"><p>Estimate the magnitude of the ADA effect on PK (and drug exposure) to assess clinical importance (in conjunction with other clinical considerations)</p><p>Re-evaluate time-dependent PK when ADA effects are added to the model, including differences between tumor types (or other important covariates from the graphical analyses)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">DTMM</td><td align="left" colspan="1" rowspan="1"><p>DTMM typically has few fixed effects and no or limited random effects with relatively fast run times. Due to the low computational burden DTMM are ideal for a broad covariate evaluation (e.g. SCM)</p><p>Limited changes to the data set are required if time-varying ADA data are included in the population PK data set (use ADA as DV column). Prior ADA&#160;status can be added to the data set or obtained on the run in the model control stream</p><p>Output of the individual time-course of ADA+&#8201;probability (<inline-formula id="IEq143"><alternatives><tex-math id="d33e5006">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p1$$\end{document}</tex-math><mml:math id="d33e5011"><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_Article_IEq64.gif"/></alternatives></inline-formula>) may be added to the data&#160;set for a sequential DTMM-PK model. Time-varying ADA data are usually binary (values of 0 or 1) with a step change; the DTMM provide a gradual change in ADA status with individual maximal values (range 0&#8211;1)</p></td><td align="left" colspan="1" rowspan="1"><p>Obtain population estimates for probability of ADA+&#8201;status, including at baseline</p><p>Covariate relationships are not time-consuming and may be thoroughly assessed using automated search strategies</p><p>Covariate relationships may be included in the evaluation of the ADA as a time-varying covariate in the population PK model using a sequential DTMM-PK model</p><p>Covariate relationships for DTMM will facilitate the covariate model development/evaluation for CTMM that may be limited owing to the latter&#8217;s high computational burden</p></td></tr><tr><td align="left" colspan="1" rowspan="1">CTMM</td><td align="left" colspan="1" rowspan="1"><p>Due to the high computational burden, especially with large data sets, CTMM development could start with the most informative data set (e.g. limited to the study or tumor type with the highest quantity/quality of ADA data)</p><p>Substantial changes to the data set are required for implementation in NONMEM. The Markovian elements (prior ADA status) are incorporated as compartment amounts that are set to 1 (100% probability) or 0 (0% probability) using the associated bioavailability parameter</p><p>Long run times may limit covariate model development but may be informed by the results of a prior DTMM covariate evaluation</p><p>Random effects may not be estimable or may lack adequate precision, which may impact the development of a joint PK-ADA model (see Joint PK-ADA recommendations below)</p></td><td align="left" colspan="1" rowspan="1"><p>CTMM may be more appropriate for non-uniform observation times. However, ADA data are collected at uniform times in clinical trials, and DTMM and CTMM methods produce similar results</p><p>Reserve CTMM development for small data sets or in scenarios in which ADA data will be jointly analyzed with non-uniform data (e.g. adverse event data)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Joint PK-ADA</td><td align="left" colspan="1" rowspan="1"><p>Assess correlations in the PK and ADA model parameters (clearance and ADA transition rates) prior to combining the PK and ADA models in a joint model to assess feasibility for developing a joint model</p><p>If the population PK model is coded using sets of differential equations, combination with CTMM is feasible. As a first step the correlation in clearance and the transition rate from ADA&#8722; to ADA+&#8201;should be estimated. If the CTMM did not include IIV in transition rates, assign the estimate from the DTMM as the initial estimate or fix IIV to a large value (e.g. 2)</p></td><td align="left" colspan="1" rowspan="1"><p>The joint model may be helpful to understand differences in efficacy and/or safety profiles with dose adjustments in different studies, prior treatment experiences, or with unexpected clinical findings. This approach also enables simulations of alternate dosing regimens with respect to the probability/time-course of ADA development</p><p>Robust, stable population PK models and CTMM should be developed prior to developing the joint models. The computational burden will limit the number of parameters that may be estimated (depending on the size of the data set)</p><p>Depending on the complexity of the bi-directional effects, longitudinal models may be useful to answer questions relating to the effects of&#160;exposure on probability of becoming ADA+&#8201;:</p><p>- concentrations in which the probability may exceed a specific threshold (e.g. 50%) and to relate this point to concentration ranges for specific tumor types, or concentrations of interest (e.g. Cmax or trough concentrations);</p><p>- the impact of increasing concentrations of drug on the probability of becoming ADA+&#8201;;</p><p>- the probability of becoming ADA+&#8201;at time-points of interest to simplify the protocol requirements for ADA data collection</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec15"><title>Conclusions</title><p id="Par57">This analysis investigated approaches to quantitatively account for immunogenicity in an immuno-oncology setting for an immune checkpoint inhibitory monoclonal antibody. The approaches included ADA as a covariate in a population PK model and Markov models of ADA status (ADA+&#8201;or ADA&#8722;). The final joint PK-ADA model incorporated bidirectional effects of ADA status on avelumab clearance and avelumab exposure on ADA status. None of the investigated covariates other than baseline ADA status and tumor type were of relevance for assessing avelumab immunogenicity. The joint PK-ADA model estimated a lower rate of change from ADA&#8722; to ADA+&#8201;status with higher avelumab concentrations. Viewed from a broader perspective, the analyses presented here illustrate a roadmap for approaching quantitative characterization of the inter-relationships of dynamics of PK and ADA for quantitative clinical pharmacology characterization of biologics.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10928_2025_9971_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 115 kb)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contribution</title><p>J.S.W., J.W. and A.-M.M.-G. wrote the manuscript. A.K., A.-M.M.-G., J.W., J.S.W. and K.V. designed the research. J.S.W. and J.W. performed the research. All authors analyzed the data. All authors reviewed and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The study was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to the healthcare business of Merck KGaA, Darmstadt, Germany&#8217;s (CrossRef Funder ID: 10.13039/100009945) Data Sharing Policy. All requests should be submitted in writing to the healthcare business of Merck KGaA, Darmstadt, Germany's data sharing portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html">https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ext-link>). When the healthcare business of Merck KGaA, Darmstadt, Germany has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, the healthcare business of Merck KGaA, Darmstadt, Germany will endeavor to gain agreement to share data in response to requests.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par58">JSvdW and JJW were employed as consultants by Merck KGaA when analyses were performed. AK was an&#160;employee of the healthcare business of Merck KGaA, Darmstadt, Germany at time of the analysis. KV is an employee of EMD Serono, Billerica, MA, USA. WG was an employee of EMD Serono, Billerica, MA, USA at time of the analysis. AMM is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanson</surname><given-names>SJ</given-names></name></person-group><article-title>Immunogenicity issues in drug development</article-title><source>J Immunotoxicol</source><year>2006</year><volume>3</volume><issue>3</issue><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1080/15476910600908852</pub-id><pub-id pub-id-type="pmid">18958697</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Swanson SJ (2006) Immunogenicity issues in drug development. J Immunotoxicol 3(3):165&#8211;172. 10.1080/15476910600908852<pub-id pub-id-type="pmid">18958697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15476910600908852</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enrico</surname><given-names>D</given-names></name><name name-style="western"><surname>Paci</surname><given-names>A</given-names></name><name name-style="western"><surname>Chaput</surname><given-names>N</given-names></name><name name-style="western"><surname>Karamouza</surname><given-names>E</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B</given-names></name></person-group><article-title>Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation?</article-title><source>Clin Cancer Res</source><year>2020</year><volume>26</volume><issue>4</issue><fpage>787</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-2337</pub-id><pub-id pub-id-type="pmid">31757876</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Enrico D, Paci A, Chaput N, Karamouza E, Besse B (2020) Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin Cancer Res 26(4):787&#8211;792. 10.1158/1078-0432.CCR-19-2337<pub-id pub-id-type="pmid">31757876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-2337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jani</surname><given-names>M</given-names></name><name name-style="western"><surname>Barton</surname><given-names>A</given-names></name><name name-style="western"><surname>Warren</surname><given-names>RB</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Chinoy</surname><given-names>H</given-names></name></person-group><article-title>The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases</article-title><source>Rheumatology (Oxford)</source><year>2014</year><volume>53</volume><issue>2</issue><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ket260</pub-id><pub-id pub-id-type="pmid">23946436</pub-id><pub-id pub-id-type="pmcid">PMC3894670</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H (2014) The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 53(2):213&#8211;222. 10.1093/rheumatology/ket260<pub-id pub-id-type="pmid">23946436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/ket260</pub-id><pub-id pub-id-type="pmcid">PMC3894670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez</surname><given-names>L</given-names></name><name name-style="western"><surname>Bustos</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zapata</surname><given-names>C</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J</given-names></name><name name-style="western"><surname>Jauregui</surname><given-names>E</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>GM</given-names></name></person-group><article-title>Immunogenicity in protein and peptide based-therapeutics: an overview</article-title><source>Curr Protein Pept Sci</source><year>2018</year><volume>19</volume><issue>10</issue><fpage>958</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.2174/1389203718666170828123449</pub-id><pub-id pub-id-type="pmid">28847291</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Fernandez L, Bustos RH, Zapata C, Garcia J, Jauregui E, Ashraf GM (2018) Immunogenicity in protein and peptide based-therapeutics: an overview. Curr Protein Pept Sci 19(10):958&#8211;971. 10.2174/1389203718666170828123449<pub-id pub-id-type="pmid">28847291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389203718666170828123449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatarewicz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Mytych</surname><given-names>DT</given-names></name><name name-style="western"><surname>Manning</surname><given-names>MS</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Moxness</surname><given-names>MS</given-names></name><name name-style="western"><surname>Chirmule</surname><given-names>N</given-names></name></person-group><article-title>Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact</article-title><source>Bioanalysis</source><year>2014</year><volume>6</volume><issue>11</issue><fpage>1509</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.4155/bio.14.114</pub-id><pub-id pub-id-type="pmid">25046051</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Tatarewicz SM, Mytych DT, Manning MS, Swanson SJ, Moxness MS, Chirmule N (2014) Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis 6(11):1509&#8211;1523. 10.4155/bio.14.114<pub-id pub-id-type="pmid">25046051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/bio.14.114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khandelwal</surname><given-names>A</given-names></name><name name-style="western"><surname>Grisic</surname><given-names>AM</given-names></name><name name-style="western"><surname>French</surname><given-names>J</given-names></name><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K</given-names></name></person-group><article-title>Pharmacometrics golems: exposure-response models in oncology</article-title><source>Clin Pharmacol Ther</source><year>2022</year><volume>112</volume><issue>5</issue><fpage>941</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1002/cpt.2564</pub-id><pub-id pub-id-type="pmid">35286713</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Khandelwal A, Grisic AM, French J, Venkatakrishnan K (2022) Pharmacometrics golems: exposure-response models in oncology. Clin Pharmacol Ther 112(5):941&#8211;945. 10.1002/cpt.2564<pub-id pub-id-type="pmid">35286713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>G</given-names></name><name name-style="western"><surname>Suryawanshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Roy</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology</article-title><source>Br J Clin Pharmacol</source><year>2019</year><volume>85</volume><issue>9</issue><fpage>2045</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1111/bcp.13996</pub-id><pub-id pub-id-type="pmid">31140642</pub-id><pub-id pub-id-type="pmcid">PMC6710515</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bajaj G, Suryawanshi S, Roy A, Gupta M (2019) Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. Br J Clin Pharmacol 85(9):2045&#8211;2058. 10.1111/bcp.13996<pub-id pub-id-type="pmid">31140642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13996</pub-id><pub-id pub-id-type="pmcid">PMC6710515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gulley</surname><given-names>JL</given-names></name></person-group><article-title>Product review: avelumab, an anti-PD-L1 antibody</article-title><source>Hum Vaccin Immunother</source><year>2019</year><volume>15</volume><issue>4</issue><fpage>891</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1551671</pub-id><pub-id pub-id-type="pmid">30481100</pub-id><pub-id pub-id-type="pmcid">PMC6605872</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Collins JM, Gulley JL (2019) Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother 15(4):891&#8211;908. 10.1080/21645515.2018.1551671<pub-id pub-id-type="pmid">30481100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2018.1551671</pub-id><pub-id pub-id-type="pmcid">PMC6605872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Bavencio (avelumab) 2024 Summary of product characteristics. Merck Europe B.V., Amsterdam, Netherlands, an affiliate of Merck KGaA.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ooi</surname><given-names>QX</given-names></name><name name-style="western"><surname>Plan</surname><given-names>E</given-names></name><name name-style="western"><surname>Bergstrand</surname><given-names>M</given-names></name></person-group><article-title>A tutorial on pharmacometric Markov models</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2025</year><volume>14</volume><issue>2</issue><fpage>197</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1002/psp4.13278</pub-id><pub-id pub-id-type="pmid">39670923</pub-id><pub-id pub-id-type="pmcid">PMC11812945</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Ooi QX, Plan E, Bergstrand M (2025) A tutorial on pharmacometric Markov models. CPT Pharmacometrics Syst Pharmacol 14(2):197&#8211;216. 10.1002/psp4.13278<pub-id pub-id-type="pmid">39670923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.13278</pub-id><pub-id pub-id-type="pmcid">PMC11812945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkins</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Brockhaus</surname><given-names>B</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Vugmeyster</surname><given-names>Y</given-names></name><name name-style="western"><surname>White</surname><given-names>JT</given-names></name><name name-style="western"><surname>Brar</surname><given-names>S</given-names></name><name name-style="western"><surname>Bello</surname><given-names>CL</given-names></name><name name-style="western"><surname>Neuteboom</surname><given-names>B</given-names></name><name name-style="western"><surname>Wade</surname><given-names>JR</given-names></name><name name-style="western"><surname>Girard</surname><given-names>P</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>A</given-names></name></person-group><article-title>Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2019</year><volume>8</volume><issue>6</issue><fpage>415</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1002/psp4.12406</pub-id><pub-id pub-id-type="pmid">30980481</pub-id><pub-id pub-id-type="pmcid">PMC6617853</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A (2019) Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma. CPT Pharmacometrics Syst Pharmacol 8(6):415&#8211;427. 10.1002/psp4.12406<pub-id pub-id-type="pmid">30980481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12406</pub-id><pub-id pub-id-type="pmcid">PMC6617853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>P</given-names></name><name name-style="western"><surname>Dai</surname><given-names>HI</given-names></name><name name-style="western"><surname>Bourdage</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Trang</surname><given-names>K</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>K</given-names></name><name name-style="western"><surname>Bello</surname><given-names>C</given-names></name><name name-style="western"><surname>Hibma</surname><given-names>J</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>A</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>K</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name></person-group><article-title>Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma</article-title><source>Clin Transl Sci</source><year>2024</year><volume>17</volume><issue>3</issue><fpage>e13730</fpage><pub-id pub-id-type="doi">10.1111/cts.13730</pub-id><pub-id pub-id-type="pmid">38411318</pub-id><pub-id pub-id-type="pmcid">PMC10897865</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Hu P, Dai HI, Bourdage J, Zhou D, Trang K, Kowalski K, Bello C, Hibma J, Khandelwal A, Cowan K, Dong J, Venkatakrishnan K, Gao W (2024) Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma. Clin Transl Sci 17(3):e13730. 10.1111/cts.13730<pub-id pub-id-type="pmid">38411318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13730</pub-id><pub-id pub-id-type="pmcid">PMC10897865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Maher</surname><given-names>VE</given-names></name><name name-style="western"><surname>Booth</surname><given-names>BP</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis</article-title><source>Clin Pharmacol Ther</source><year>2017</year><volume>101</volume><issue>5</issue><fpage>657</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1002/cpt.656</pub-id><pub-id pub-id-type="pmid">28182273</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Liu C, Yu J, Li H, Liu J, Xu Y, Song P, Liu Q, Zhao H, Xu J, Maher VE, Booth BP, Kim G, Rahman A, Wang Y (2017) Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther 101(5):657&#8211;666. 10.1002/cpt.656<pub-id pub-id-type="pmid">28182273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Holford</surname><given-names>NH</given-names></name></person-group><article-title>Mechanism-based concepts of size and maturity in pharmacokinetics</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2008</year><volume>48</volume><fpage>303</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.48.113006.094708</pub-id><pub-id pub-id-type="pmid">17914927</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303&#8211;332. 10.1146/annurev.pharmtox.48.113006.094708<pub-id pub-id-type="pmid">17914927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pharmtox.48.113006.094708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>RC</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>B</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AF</given-names></name><name name-style="western"><surname>van Gerven</surname><given-names>JM</given-names></name><name name-style="western"><surname>Tuk</surname><given-names>B</given-names></name><name name-style="western"><surname>Peck</surname><given-names>CC</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name></person-group><article-title>A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>68</volume><issue>2</issue><fpage>175</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.108669</pub-id><pub-id pub-id-type="pmid">10976549</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Karlsson MO, Schoemaker RC, Kemp B, Cohen AF, van Gerven JM, Tuk B, Peck CC, Danhof M (2000) A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin Pharmacol Ther 68(2):175&#8211;188. 10.1067/mcp.2000.108669<pub-id pub-id-type="pmid">10976549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.108669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Snelder N, Diack C, Benson N, Ploeger B (2009) Towards the implementation of the Markov property into a continuous-time transition state model in NONMEM. PAGE. 18: 1536</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergstrand</surname><given-names>M</given-names></name><name name-style="western"><surname>Soderlind</surname><given-names>E</given-names></name><name name-style="western"><surname>Weitschies</surname><given-names>W</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics</article-title><source>Clin Pharmacol Ther</source><year>2009</year><volume>86</volume><issue>1</issue><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/clpt.2009.43</pub-id><pub-id pub-id-type="pmid">19387437</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Bergstrand M, Soderlind E, Weitschies W, Karlsson MO (2009) Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. Clin Pharmacol Ther 86(1):77&#8211;83. 10.1038/clpt.2009.43<pub-id pub-id-type="pmid">19387437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2009.43</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Karlsson M (2012) Introduction to Markov modelling. PAGE. 21: 2636</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (2016) NONMEM Users&#8217; Guides. Ellicott City, Maryland, USA: ICON Development Solutions.</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savic</surname><given-names>RM</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions</article-title><source>AAPS J</source><year>2009</year><volume>11</volume><issue>3</issue><fpage>558</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1208/s12248-009-9133-0</pub-id><pub-id pub-id-type="pmid">19649712</pub-id><pub-id pub-id-type="pmcid">PMC2758126</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558&#8211;569. 10.1208/s12248-009-9133-0<pub-id pub-id-type="pmid">19649712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-009-9133-0</pub-id><pub-id pub-id-type="pmcid">PMC2758126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindbom</surname><given-names>L</given-names></name><name name-style="western"><surname>Ribbing</surname><given-names>J</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name></person-group><article-title>Perl-speaks-NONMEM (PsN)&#8211;a Perl module for NONMEM related programming</article-title><source>Comput Methods Programs Biomed</source><year>2004</year><volume>75</volume><issue>2</issue><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2003.11.003</pub-id><pub-id pub-id-type="pmid">15212851</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)&#8211;a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85&#8211;94. 10.1016/j.cmpb.2003.11.003<pub-id pub-id-type="pmid">15212851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2003.11.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindbom</surname><given-names>L</given-names></name><name name-style="western"><surname>Pihlgren</surname><given-names>P</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name></person-group><article-title>PsN-Toolkit&#8211;a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM</article-title><source>Comput Methods Programs Biomed</source><year>2005</year><volume>79</volume><issue>3</issue><fpage>241</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2005.04.005</pub-id><pub-id pub-id-type="pmid">16023764</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit&#8211;a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241&#8211;257. 10.1016/j.cmpb.2005.04.005<pub-id pub-id-type="pmid">16023764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2005.04.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>J</given-names></name></person-group><article-title>A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2022</year><volume>11</volume><issue>6</issue><fpage>673</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1002/psp4.12790</pub-id><pub-id pub-id-type="pmid">35353958</pub-id><pub-id pub-id-type="pmcid">PMC9197539</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jonsson EN, Nyberg J (2022) A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses. CPT Pharmacometrics Syst Pharmacol 11(6):673&#8211;686. 10.1002/psp4.12790<pub-id pub-id-type="pmid">35353958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12790</pub-id><pub-id pub-id-type="pmcid">PMC9197539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vugmeyster</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grisic</surname><given-names>AM</given-names></name><name name-style="western"><surname>Brockhaus</surname><given-names>B</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruisi</surname><given-names>M</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>A</given-names></name></person-group><article-title>Avelumab dose selection for clinical studies in pediatric patients with solid tumors</article-title><source>Clin Pharmacokinet</source><year>2022</year><volume>61</volume><issue>7</issue><fpage>985</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1007/s40262-022-01111-8</pub-id><pub-id pub-id-type="pmid">35484319</pub-id><pub-id pub-id-type="pmcid">PMC9287219</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Vugmeyster Y, Grisic AM, Brockhaus B, Rueckert P, Ruisi M, Dai H, Khandelwal A (2022) Avelumab dose selection for clinical studies in pediatric patients with solid tumors. Clin Pharmacokinet 61(7):985&#8211;995. 10.1007/s40262-022-01111-8<pub-id pub-id-type="pmid">35484319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-022-01111-8</pub-id><pub-id pub-id-type="pmcid">PMC9287219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Lawrence Gould A, Boye ME, Crowther MJ, Ibrahim JG, Quartey G, Micallef S, Bois FY (2015) Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. Stat Med. 34 (14): 2181&#8211;2195. 10.1002/sim.6141<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6141</pub-id><pub-id pub-id-type="pmcid">PMC4677775</pub-id><pub-id pub-id-type="pmid">24634327</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>GL</given-names></name><name name-style="western"><surname>Philipson</surname><given-names>P</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>A</given-names></name><name name-style="western"><surname>Kolamunnage-Dona</surname><given-names>R</given-names></name></person-group><article-title>Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues</article-title><source>BMC Med Res Methodol</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/s12874-016-0212-5</pub-id><pub-id pub-id-type="pmid">27604810</pub-id><pub-id pub-id-type="pmcid">PMC5015261</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R (2016) Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues. BMC Med Res Methodol 16(1):117. 10.1186/s12874-016-0212-5<pub-id pub-id-type="pmid">27604810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12874-016-0212-5</pub-id><pub-id pub-id-type="pmcid">PMC5015261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirks</surname><given-names>NL</given-names></name><name name-style="western"><surname>Meibohm</surname><given-names>B</given-names></name></person-group><article-title>Population pharmacokinetics of therapeutic monoclonal antibodies</article-title><source>Clin Pharmacokinet</source><year>2010</year><volume>49</volume><issue>10</issue><fpage>633</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.2165/11535960-000000000-00000</pub-id><pub-id pub-id-type="pmid">20818831</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633&#8211;659. 10.2165/11535960-000000000-00000<pub-id pub-id-type="pmid">20818831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11535960-000000000-00000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Niebecker R, Kloft C (2012) Modelling of anti-drug antibodies directed against a monoclonal antibody. PAGE. 21: 2432</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayoun Alsoud</surname><given-names>R</given-names></name><name name-style="western"><surname>Le Moan</surname><given-names>N</given-names></name><name name-style="western"><surname>Holten-Andersen</surname><given-names>L</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Lennernas</surname><given-names>H</given-names></name><name name-style="western"><surname>Simonsson</surname><given-names>USH</given-names></name></person-group><article-title>Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein</article-title><source>J Pharm Sci</source><year>2024</year><volume>113</volume><issue>9</issue><fpage>2895</fpage><lpage>2903</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2024.06.022</pub-id><pub-id pub-id-type="pmid">38945365</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ayoun Alsoud R, Le Moan N, Holten-Andersen L, Knudsen T, Lennernas H, Simonsson USH (2024) Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein. J Pharm Sci 113(9):2895&#8211;2903. 10.1016/j.xphs.2024.06.022<pub-id pub-id-type="pmid">38945365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2024.06.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Beal</surname><given-names>SL</given-names></name><name name-style="western"><surname>Sheiner</surname><given-names>LB</given-names></name></person-group><article-title>Simultaneous vs sequential analysis for population PK/PD data I: best-case performance</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2003</year><volume>30</volume><issue>6</issue><fpage>387</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1023/b:jopa.0000012998.04442.1f</pub-id><pub-id pub-id-type="pmid">15000421</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30(6):387&#8211;404. 10.1023/b:jopa.0000012998.04442.1f<pub-id pub-id-type="pmid">15000421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/b:jopa.0000012998.04442.1f</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Parra-Guillen ZP, Troc&#243;niz IF, Freshwater T (2023) Modeling the dynamics of anti-drug antibodies in cancer patients treated with oncolytic virus in monotherapy or in combination with immune check- point inhibitors. PAGE 31: 10687</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Lacroix BD, Kirby H, Oliver R, Parker G, Friberg LE, Karlsson MO (2015) A time-to-event model for the immunogenicity of certolizumab pegol in rheumatoid arthritis subjects. PAGE 24: 3554</mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>HI</given-names></name><name name-style="western"><surname>Vugmeyster</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mangal</surname><given-names>N</given-names></name></person-group><article-title>Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><issue>6</issue><fpage>1156</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1002/cpt.1953</pub-id><pub-id pub-id-type="pmid">32557643</pub-id><pub-id pub-id-type="pmcid">PMC7689749</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Dai HI, Vugmeyster Y, Mangal N (2020) Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther 108(6):1156&#8211;1170. 10.1002/cpt.1953<pub-id pub-id-type="pmid">32557643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1953</pub-id><pub-id pub-id-type="pmcid">PMC7689749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leisegang</surname><given-names>R</given-names></name><name name-style="western"><surname>Silber Baumann</surname><given-names>HE</given-names></name><name name-style="western"><surname>Lennon-Chrimes</surname><given-names>S</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name><name name-style="western"><surname>Miya</surname><given-names>K</given-names></name><name name-style="western"><surname>Genin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Plan</surname><given-names>EL</given-names></name></person-group><article-title>Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2024</year><volume>13</volume><issue>12</issue><fpage>2171</fpage><lpage>2184</lpage><pub-id pub-id-type="doi">10.1002/psp4.13230</pub-id><pub-id pub-id-type="pmid">39380259</pub-id><pub-id pub-id-type="pmcid">PMC11646947</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Leisegang R, Silber Baumann HE, Lennon-Chrimes S, Ito H, Miya K, Genin JC, Plan EL (2024) Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model. CPT Pharmacometrics Syst Pharmacol 13(12):2171&#8211;2184. 10.1002/psp4.13230<pub-id pub-id-type="pmid">39380259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.13230</pub-id><pub-id pub-id-type="pmcid">PMC11646947</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brekkan</surname><given-names>A</given-names></name><name name-style="western"><surname>Lledo-Garcia</surname><given-names>R</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>B</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>S</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Plan</surname><given-names>EL</given-names></name></person-group><article-title>Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-Markov model by nonlinear-mixed effects approach</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2024</year><volume>51</volume><issue>1</issue><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s10928-023-09890-8</pub-id><pub-id pub-id-type="pmid">37943398</pub-id><pub-id pub-id-type="pmcid">PMC10884144</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Brekkan A, Lledo-Garcia R, Lacroix B, Jonsson S, Karlsson MO, Plan EL (2024) Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-Markov model by nonlinear-mixed effects approach. J Pharmacokinet Pharmacodyn 51(1):65&#8211;75. 10.1007/s10928-023-09890-8<pub-id pub-id-type="pmid">37943398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10928-023-09890-8</pub-id><pub-id pub-id-type="pmcid">PMC10884144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usdin</surname><given-names>M</given-names></name><name name-style="western"><surname>Quarmby</surname><given-names>V</given-names></name><name name-style="western"><surname>Zanghi</surname><given-names>J</given-names></name><name name-style="western"><surname>Bernaards</surname><given-names>C</given-names></name><name name-style="western"><surname>Liao</surname><given-names>L</given-names></name><name name-style="western"><surname>Laxamana</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Siguenza</surname><given-names>P</given-names></name></person-group><article-title>Immunogenicity of atezolizumab: influence of testing method and sampling frequency on reported anti-drug antibody incidence rates</article-title><source>AAPS J</source><year>2024</year><volume>26</volume><issue>4</issue><fpage>84</fpage><pub-id pub-id-type="doi">10.1208/s12248-024-00954-2</pub-id><pub-id pub-id-type="pmid">39009791</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Usdin M, Quarmby V, Zanghi J, Bernaards C, Liao L, Laxamana J, Wu B, Swanson S, Song Y, Siguenza P (2024) Immunogenicity of atezolizumab: influence of testing method and sampling frequency on reported anti-drug antibody incidence rates. AAPS J 26(4):84. 10.1208/s12248-024-00954-2<pub-id pub-id-type="pmid">39009791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-024-00954-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Devanarayan V (2016) Interpretation of immunogenicity results and evaluation of clinical associations. Presentation at the European Bioanalysis Forum 9th Open Meeting. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.e-b-f.eu/wp-content/uploads/2018/06/bcn2016-D2J4-4-Viswanath-Devanarayan_Abbvie.pdf">https://www.e-b-f.eu/wp-content/uploads/2018/06/bcn2016-D2J4-4-Viswanath-Devanarayan_Abbvie.pdf</ext-link>.</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Brummelen</surname><given-names>EM</given-names></name><name name-style="western"><surname>Ros</surname><given-names>W</given-names></name><name name-style="western"><surname>Wolbink</surname><given-names>G</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name></person-group><article-title>Antidrug antibody formation in oncology: clinical relevance and challenges</article-title><source>Oncologist</source><year>2016</year><volume>21</volume><issue>10</issue><fpage>1260</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0061</pub-id><pub-id pub-id-type="pmid">27440064</pub-id><pub-id pub-id-type="pmcid">PMC5061540</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH (2016) Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist 21(10):1260&#8211;1268. 10.1634/theoncologist.2016-0061<pub-id pub-id-type="pmid">27440064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2016-0061</pub-id><pub-id pub-id-type="pmcid">PMC5061540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Vugt</surname><given-names>MJH</given-names></name><name name-style="western"><surname>Stone</surname><given-names>JA</given-names></name><name name-style="western"><surname>De Greef</surname><given-names>R</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>ES</given-names></name><name name-style="western"><surname>Lipka</surname><given-names>L</given-names></name><name name-style="western"><surname>Turner</surname><given-names>DC</given-names></name><name name-style="western"><surname>Chain</surname><given-names>A</given-names></name><name name-style="western"><surname>Lala</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Robey</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kondic</surname><given-names>AG</given-names></name><name name-style="western"><surname>De Alwis</surname><given-names>D</given-names></name><name name-style="western"><surname>Mayawala</surname><given-names>K</given-names></name><name name-style="western"><surname>Jain</surname><given-names>L</given-names></name><name name-style="western"><surname>Freshwater</surname><given-names>T</given-names></name></person-group><article-title>Immunogenicity of pembrolizumab in patients with advanced tumors</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><issue>1</issue><fpage>212</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0663-4</pub-id><pub-id pub-id-type="pmid">31395089</pub-id><pub-id pub-id-type="pmcid">PMC6686242</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">van Vugt MJH, Stone JA, De Greef R, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T (2019) Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer 7(1):212. 10.1186/s40425-019-0663-4<pub-id pub-id-type="pmid">31395089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0663-4</pub-id><pub-id pub-id-type="pmcid">PMC6686242</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>S</given-names></name><name name-style="western"><surname>Galle</surname><given-names>PR</given-names></name><name name-style="western"><surname>Bernaards</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ballinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R</given-names></name><name name-style="western"><surname>Quarmby</surname><given-names>V</given-names></name><name name-style="western"><surname>Ruppel</surname><given-names>J</given-names></name><name name-style="western"><surname>Vilimovskij</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><name name-style="western"><surname>Sternheim</surname><given-names>N</given-names></name><name name-style="western"><surname>Reck</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of atezolizumab immunogenicity: efficacy and safety (part 2)</article-title><source>Clin Transl Sci</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>141</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1111/cts.13149</pub-id><pub-id pub-id-type="pmid">34582105</pub-id><pub-id pub-id-type="pmcid">PMC8742640</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, Ruppel J, Vilimovskij A, Wu B, Sternheim N, Reck M (2022) Evaluation of atezolizumab immunogenicity: efficacy and safety (part 2). Clin Transl Sci 15(1):141&#8211;157. 10.1111/cts.13149<pub-id pub-id-type="pmid">34582105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13149</pub-id><pub-id pub-id-type="pmcid">PMC8742640</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>